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β-defensins are a class of mammalian defence peptides with therapeutic potential 
because of their ability to kill bacteria and attract host immune cells.  In order to 
realise this potential, it is necessary to understand how the functions of these peptides 
are related to their structures.  This thesis presents biophysical analysis of β-
defensins and related peptides in conjunction with biological assays.  These studies 
provide new insights into the structure-activity relationships of β-defensins. 
Ion mobility-mass spectrometry (IM-MS) is used throughout this thesis to probe the 
tertiary structure of peptides in vacuo and, by inference, make conclusions about 
their conformations in solution prior to ionisation.  Where appropriate, IM-MS is 
complemented by other techniques, including high performance liquid 
chromatography and circular dichroism spectroscopy. 
First, the importance of a C-terminal cysteine residue within the murine β-defensin 
Defb14 is investigated.  The functional and structural implications of chemically 
modifying the cysteine residue are examined.  Second, the N-terminal region of 
Defb14 is modified by the substitution and deletion of amino acids.  Again, the 
effects on biological activity and structure are discussed. 
Finally, the functional and structural overlap of β-defensins with another family of 
proteins – the chemokines – is considered.  The oligomerisation of β-defensins and 
their interaction with glycosaminoglycans is of particular interest: structural data for 
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ANOVA analysis of variance 
ATD arrival time distribution 
BBD bovine -defensin 
CCL CC chemokine ligand 
CCR CC chemokine receptor 
CD circular dichroism 
cGMP cyclic guanosine monophosphate 
CPK Corey Pauling Koltun (colouring convention) 
CXCL CXC chemokine ligand 
DC direct current 
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IM-MS ion mobility-mass spectrometry 
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d distance 
e elementary charge ( = 1.6021765 × 10−19 C) 
E electric field strength 
Ek kinetic energy  
K (ion) mobility 
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m/z mass-to-charge ratio 
N number density 
p probability 
P pressure 
q net charge 
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1.1 Antimicrobial peptides 
1.1.1 Therapeutic potential 
Antimicrobial resistance is, according to the World Health Organization, “a global 
problem that needs urgent action”.1  The inevitability that bacteria will develop 
resistance to an antibiotic in clinical use means that there is a continual requirement 
for the discovery of new drugs.  However, there is a dearth of such compounds in the 
pharmaceutical pipeline,2 resulting in a decreasing number of treatments available for 
serious bacterial infections.3  As such, there is a clear need to develop new classes of 
antibiotics with novel modes of action. 
Antimicrobial peptides are a relatively untapped source of molecules with 
therapeutic potential.  In nature, almost every organism uses cationic antimicrobial 
peptides as part of its arsenal to combat infection.4, 5  These peptides comprise part of 
the innate immune system: a series of non-specific mechanisms to overcome 
invasion by microorganisms.  The antibiotics polymixin B and gramicidin S are 
antimicrobial peptides derived from bacteria and have been in clinical use for many 
years.6  Antibiotics from the antimicrobial peptides of higher organisms have yet to 
be used. 
The interest in antimicrobial peptides stems from their broad-spectrum of 
antimicrobial activities and their rapid action.  Conventional drug development 
generally favours the concept of a single drug for an individual target.3  In contrast, 
within a given mammal, a number of antimicrobial peptides often have overlapping 
activities and may interact with different biological processes.7  As a result, it is more 
difficult for bacteria to develop resistance.8, 9 
The greatest obstacle to the development of antimicrobial peptides as drugs is their 
high cost of manufacture by solid-phase chemical synthesis.7  Recombinant 
expression methods may be less expensive but, thus far, few of these systems have 
generated peptides at a sufficient quantity and purity for commercial use.10  It is 
therefore desirable to design shorter, functional analogues of wild-type peptides that 
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are cheaper to produce.  This requires identifying which parts of the structure are 
important to its biological activity. 
1.1.2 General structure 
Antimicrobial peptides are short proteins of approximately 10 – 50 amino acids.4, 5  
There is a high degree of variation in the primary structure of these peptides: rapid 
evolution is believed to occur as a result of selective pressure to contend with the 
development of bacterial resistance.8  Most sequences comprise a large number of 
basic residues, giving the peptide an overall positive charge, in addition to a 
significant number of hydrophobic amino residues.  In three dimensional space the 
peptide may adopt an amphipathic structure, such that distinct regions of high 
positive charge and high hydrophobicity are formed.  Antimicrobial peptides can be 
loosely classified according to their secondary structure content (Figure 1.1): the 
main categories being those consisting mainly of -sheet (including defensins) and 
those that are predominantly -helical (including cathelicidins and magainins). 
1.1.3 Modes of action 
The first step in the mechanism of antimicrobial action involves the accumulation of 
the peptides at the microbial surface.11  This occurs via electrostatic attraction of the 
cationic peptides to the negatively-charged components of the outer bacterial cell 
wall: lipopolysaccharides in Gram-negative bacteria and teichoic acids in the Gram-
positive bacteria (Figure 1.2).  Thereafter the peptides may kill the bacteria either: by 
permeation through the membrane (without inducing permanent damage) and 
subsequent action upon an intracellular target; or by lysis of the cell membrane.11  
There are two major theories as to how the latter may occur: the pore model12 and the 
carpet model.13  In both the pore and carpet models, bacterial death results through 
leakage of the cytoplasmic contents from the cell. 
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Figure 1.1 Secondary structure motifs 
 
Reproduced with permission from The Pennsylvania State University. 
In the pore model (Figure 1.3a), a series of peptides insert into the bacterial 
membrane and re-orientate themselves perpendicular to the phospholipid bilayer.  
These peptides group together to form an oligomer that forces each phospholipid 
layer to bend until a toroidal pore is formed.  In the carpet model (Figure 1.3b), 
peptides accumulate at the surface of the membrane, weakening the integrity of the 
bilayer.  The peptides act like surfactant molecules: once a critical concentration is 























The above schematic illustrates the cell walls of (a) Gram-negative and (b) Gram-positive 
bacteria.  The Gram-positive bacterial cell wall consists of only two layers: the inner 
membrane and a thicker peptidoglycan layer.  Teichoic acids protrude from the outer surface 
of Gram-positive bacteria, similar to the lipopolysaccharides in Gram-negative bacteria. 
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Figure 1.3 Models of antimicrobial action 
a) b)
 
The above schematic shows: (a) the toroidal pore model; and (b) the carpet model.  
Hydrophilic regions of the peptide are coloured red, hydrophobic regions are coloured blue.  
Images are taken from ref (11). 
1.2 Defensins 
1.2.1 Classification and expression 
Defensins are an important class of antimicrobial peptides found in plants and 
animals that have therapeutic potential on account of their broad-spectrum activity 
towards Gram-positive and Gram-negative bacteria, fungi and viruses.14-16  Defensins 
contain six highly-conserved cysteine residues and are classified into ,  or sub-
families according to the pattern of disulfide bonding that occurs between these 
amino acids (Table 1.1).  
Table 1.1 Classification of defensins 
Sub-family Cysteine connectivity 
 CysI-CysVI CysII-CysIV CysIII-CysV 
 CysI-CysV CysII-CysIV CysIII-CysVI 
 CysI-CysVI CysII-CysV CysIII-CysIV 
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Both - and -defensins are found in humans, with -defensins being expressed only 
in a number of monkey and ape species.17  Interestingly, humans do contain genes 
that code for -defensins but these contain mutations that introduce stop codons in 
the mRNA, terminating peptide translation.18  This thesis focuses entirely on the -
defensin class of antimicrobial peptides. 
In mammals, -defensins are expressed mainly in epithelial cells and leukocytes.15  
To date, three human -defensins (HBDs) have been isolated: HBD1 from blood 
filtrate,19 HBD2 and HBD3 from psoriatic scales.20, 21  The sequences of several 
more have been predicted from computational searching of the human genome.22  
HBD1 is present at nanomolar levels in human plasma and is expressed 
constitutively: that is to say that the peptide is always present at a constant 
concentration.  In contrast, the production of HBD2 and HBD3 is induced upon 
bacterial challenge and during inflammation.14  
1.2.2 Structure 
Like many other antimicrobial peptides, -defensins are small (3 – 6 kDa), cationic 
and amphipathic.14, 16, 23  As shown in Figure 1.4, there is very little sequence 
homology between the different -defensins, except for the six highly-conserved 
cysteine residues and two or three glycines, whose flexibility is important in an 
otherwise rigid three-dimensional fold.24  
Despite the variation in primary structure, analysis by NMR spectroscopy and X-ray 
crystallography reveals a remarkable similarity in tertiary structure.25-28  -defensins 
contain a -sheet region consisting of three anti-parallel strands, in addition to a short 
-helical section near the N-terminus (Figure 1.5).  The three disulfide bonds help to 
stabilise the three-dimensional fold.  This compact geometry results in the peptide 
being more resistant to digestion by proteolytic enzymes. 
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Shown are the amino acid sequences for a range of human (HBD), mouse (MBD) and 
bovine (BBD) -defensins. Highly conserved residues are shaded black, moderately 
conserved residues are shaded grey.  Regions of secondary structure (-helix and -strand) 
are indicated beneath the sequences.  Figure modified from ref (24). 
Figure 1.5 Tertiary structure of a -defensin 
 
Shown above is a cartoon of HBD3 (ref 28), whose three-dimensional structure is typical of 
the -defensin family of peptides.  The -helical region is coloured red; the three -strands 
are coloured yellow. The six cysteine residues are shown in black. 
At sub-millimolar concentrations, most -defensins are present as monomers in 
solution.24, 27, 28  In the crystal structure, however, HBD2 is observed as a dimer and 
an octamer (effectively a tetramer of dimers).26  Several solution-phase methods have 
 HBD1:  ......DHYNCVSSGGQCLYSACPIFTKIQGTCYRGKAKCCK... 
 HBD2:  ...GIGDPVTCLKSGAICHPVFCPRRYKQIGTCGLPGTKCCKKP. 
 HBD3:  GIINTLQKYYCRVRGGRCAVLSCLPKEEQIGKCSTRGRKCCRRKK 
 MBD1:  ......DQYKCLQHGGFCLRSSCPSNTKLQGTCKPDKPNCCKS.. 
 MBD2:  .....AELDHCHTNGGYCVRAICPPSARRPGSCFPEKNPCCKYMK 
 MBD3:  ....INNPVSCLRKGGRCWN.RCIGNTRQIGSCGVPFLKCCKRK. 
 BBD2:  ......NHVTCRINRGFCVPIRCPGRTRQIGTCFGPRIKCCRSW. 
 BBD12: ......GPLSCGRNGGVCIPIRCPVPMRQIGTCFGRPVKCCRSW. 
 
   
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determined that HBD3 exists as a dimer, although the structure of this oligomer has 
yet to be solved.28  The formation of multimers may offer the peptide greater 
protection against proteolysis as well as helping to increase the local concentration of 
the peptide at the bacterial membrane.  In addition, the oligomerisation of -
defensins could be important to the mechanism of antimicrobial action, since the 
pore model involves the formation of a higher order structure.12  Defr1 is a β-
defensin related peptide that exists as a covalently-linked dimer.29  The antimicrobial 
activity of this peptide is diminished upon modification to prevent the formation of a 
covalent dimer.30 
1.2.3 Antimicrobial activity 
Human β-defensins 1 and 2 are potent towards Gram-negative bacteria, including 
Escherichia coli and Pseudomonas aeruginosa, and fungi such as Candida 
albicans.20  In contrast, they possess only weak activity versus Gram-positive 
bacteria.  HBD3 is active against both Gram-negative and Gram-positive bacteria, 
including multi-drug resistant Staphylococcus aureus.21  In addition, unlike the other 
human β-defensins, the antimicrobial activity of HBD3 is insensitive to salt.31, 32  The 
action of some antimicrobial peptides, including HBD1 and HBD2, is attenuated by 
physiological concentrations of salt that weaken the electrostatic attraction of the 
peptide to the membrane.4  This is not the case for HBD3, perhaps because of its 
increased charge.21 
The potency of a cationic antimicrobial peptide depends greatly on its overall charge.  
For example, reduction of the positive charge in human -defensin 5 by the mutation 
of arginine to alanine resulted in a loss of activity.33  In addition, antimicrobial 
activity is strongly influenced by hydrophobicity, which affects the ability of the 
peptide to solubilise, permeate, or insert into the bacterial membrane, depending on 
the mechanism.  This was demonstrated in a study by Taylor et al., who divided a β-
defensin inspired peptide into two halves of similar charge.34  They observed that the 




1.2.4 Modes of action 
The mechanism by which defensins kill bacteria is complicated and has yet to be 
fully resolved.  Not only do different peptides possess distinct modes of action 
against the same bacterium, but each peptide may act in a variety of ways against 
different organisms.35   The -defensin sub-family has been the most studied to date 
and have been shown to form ion channels,36 larger pores,37 as well as completely 
lyse membranes.38  It has been proposed that, rather than being entirely different 
processes, each of these mechanisms are related and merely represent varying 
degrees of membrane impairment.11, 39  In addition, -defensins have also been 
shown to act against intracellular targets, inhibiting nucleotide and protein synthesis 
in E. coli.40 
Sahl and co-workers have recently investigated the killing of S. aureus by a number 
of β-defensins: HBD3, plectasin (a fungal β-defensin) and ‘tBD’ (a synthetic peptide 
based on a β-defensin template).41-43  In each case, only partial efflux of cellular 
metabolites was observed and the ingress of impermeant molecules was slow.  This 
implied that cell lysis was not the dominant mechanism of antimicrobial action.  
Instead, these peptides are believed to interfere with biosynthesis of the cell wall in 
S. aureus.  This is supported by the finding that plectasin binds Lipid II, a cell wall 
precursor.42 
One concern surrounding the clinical use of β-defensins is their potential toxicity: 
some antimicrobial peptides can interact with the membrane of human cells as well 
as those of microorganisms.7  Interactions with cells of higher organisms are usually 
weaker due to differences in the composition of the membrane, including a lack of 
negatively-charged surface lipids.  HBD3 has been shown to break down red blood 
cells in dilute medium, but not under physiological conditions.21  Several studies 
have described how it is possible to ‘tune’ the activity of HBD3 and other peptides, 
such that cytotoxicity is minimised whilst retaining antimicrobial activity.44, 45  A 
decreased number of hydrophobic residues within the peptide leads to a reduction in 
the lysis of non-target cells. 
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1.2.5 Bacterial resistance to defensins 
Despite the broad-spectrum activity of β-defensins in general, and HBD3 in 
particular, the Gram-negative bacterium Burkholderia cepacia is highly resistant to 
these peptides.46  It is believed that this is a result of a modification in its 
lipopolysaccharide: the addition of aminoarabinose molecules helps to lower its net 
negative charge and so diminishes the electrostatic attraction of the cationic peptide 
to the bacterial membrane.47 
This strategy of membrane charge reduction has been employed in various ways by 
other microorganisms and represents a possible method by which bacteria could 
potentially acquire resistance to β-defensins.48  These concerns are mitigated to some 
extent by the fact that antimicrobial peptides are “dirty drugs”, acting with a variety 
of mechanisms.7, 8  Furthermore, β-defensins possess a number of other significant 
biological functions that may prove to be more important than their antimicrobial 
activity. 
1.2.6 Chemotaxis  
In addition to their ability to kill bacteria directly, β-defensins can also recruit host 
immune cells to fight incoming pathogens.15  This occurs through the process of 
chemotaxis, whereby cells are attracted towards sites of increased β-defensin 
concentration.49  Thus, β-defensins can be considered to provide a bridge between 
innate and acquired immunity: their inherent antimicrobial activity provides an 
immediate response to counter infection, whilst the modulation of the immune 
system offers a longer-lasting response.15, 50  Given the poor antimicrobial activity of 
some β-defensins in physiological concentrations of salt, it has been suggested that 
the immunomodulatory properties of β-defensins may be more important to the host 
defense system.7 
Each of the human β-defensins isolated to date has been shown to recruit memory T 
cells and immature dendritic cells.50  The movement of these cells is believed to 
occur via an interaction between the β-defensin and the chemokine receptor CCR6, a 
G-protein coupled receptor on the surface of some cells.  In 1999, Yang et al. 
demonstrated that human embryonic kidney cells transfected with CCR6 migrated 
towards HBD3.51  Upon the addition of an antibody that blocked CCR6, chemotaxis 
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was inhibited.  In addition to memory T cells and immature dendritic cells, HBD3 
also chemoattracts monocytes.50  In this case chemotaxis must be mediated by an 
alternative, as yet unknown, receptor since monocytes do not express functional 
CCR6.52 
Whilst net charge and hydrophobicity are generally accepted to be factors that 
influence antimicrobial activity, the structural criteria for chemotactic activity are 
less clear.  Lu and collaborators found that the migration of immune cells in response 
to HBD3 was clearly affected by the connectivities of the six cysteine residues.53  
This result appeared to explain why the characteristic pattern of disulfide bonds is so 
highly conserved in β-defensins, since these intramolecular bonds are not essential to 
the antimicrobial activity of these peptides.53  However, this rationalisation is 
complicated by the discovery of HBD3 analogues that contain only a single cysteine 
residue but are equally potent chemoattractants.34  In another study, mutations of the 
N-terminal sequence of HBD1 were found to significantly decrease the peptide’s 
affinity for the receptor.54 
1.2.7 Other roles of β-defensins in vivo 
Stimulation of the immune response by chemotactic β-defensins represents a 
powerful defense mechanism, but overstimulation can result in potentially harmful 
proinflammatory responses.  Various inflammatory diseases have been linked with 
increased levels of β-defensins, including mastitis (inflammation of the mammary 
gland) and psoriasis (skin).55  Interestingly, the elevated concentration of β-defensins 
means that psoriatic lesions seldom become infected.  Conversely, atopic dermatitis, 
another inflammatory skin condition, is associated with a decreased number of β-
defensins and is susceptible to infection.56 
Undoubtedly the biological activity of β-defensins is not limited to their function as 
antimicrobials.  In 2007, Barsh and colleagues discovered that β-defensins even 
affect the hair colour of dogs!  The canine orthologue of HBD3 was found to bind a 
melanocortin receptor and therefore influences pigmentation.57  It is worth noting 
that melanocortin receptors have a range of other functions, including the 
suppression of inflammation.58 
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1.3 Investigating peptide structure-activity relationships 
As the understanding of the roles of β-defensins develops, it is apparent that much 
more work is required to fully understand the biological activity of these peptides 
and determine how that activity is related to their structure.  Studies of peptide 
structure-activity relationships broadly adopt one of two strategies: the modification 
of an existing peptide sequence or the design of a completely new peptide.59  
Following the generation of modified or novel peptides, biological testing and 
structural analysis is performed. 
1.3.1 Sequence modification 
In this type of approach, the peptide of interest is altered by the addition, deletion or 
substitution of one or more amino acids.  In order to make the synthesis of these new 
peptides practical, modification of the sequence will often be limited: either with 
regard to the number of residues that are mutated, or by the number of different 
substitutions at each position.  In an illustration of the former, Beuerman and co-
workers synthesised a range of human β-defensin 3 analogues in which only the 
cysteine residues were modified: these were replaced by amino acids of varying 
hydrophobicity.45  They observed a general correlation between greater 
hydrophobicity and increased cytotoxicity, although other factors such as the three-
dimensional structure of the peptide were also pertinent.  A recent investigation by 
Wei et al., in which each residue within human -defensin 1 was mutated 
successively to alanine, is an example of the latter methodology.60  Such an approach 
is known as ‘alanine scanning’: alanine is chosen as the replacement amino acid 
because its methyl side-chain is small and generally inert.61  In that particular study, 
the tryptophan residue at residue 26 was found to be especially important to the 
antimicrobial and antiviral activities of human -defensin 1. 
Another peptide modification used is truncation: the deletion of amino acids from 
either the N- or C-terminus.  In addition to identifying regions of the peptide that are 
key to its function, this approach has the additional potential benefit of discovering 
analogues that work but which are shorter and therefore cheaper to produce.  For 
instance, Park et al. found that the first four residues of the peptide buforin II were 
dispensable for its antimicrobial activity.62  Removal of further amino acids resulted 
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in a loss of activity due to the impairment of a helical region crucial to cell 
penetration. 
1.3.2 New peptide design  
Structure-activity relationships may also be elucidated by the design of peptides de 
novo.  Sometimes a minimalist strategy will be employed, where very few types of 
amino acid are used – typically a mix of basic and hydrophobic residues.63  This can 
be useful in identifying the minimum requirements for activity.  Alternatively, the 
peptide sequence can be based on a template, constructed following a comparison of 
homologous peptides.64   For example, Tossi and co-workers synthesised a peptide 
with defensin-like properties using a sequence obtained by identifying the most 
frequently occurring amino acids in β-defensins.43  With this approach, the aim is to 
find arrangements of amino acids that confer particular structures or properties 
important to a particular function.59 
1.4 Biophysical techniques for studying peptide structure 
1.4.1 High resolution techniques 
Of the biophysical techniques available to study peptides and proteins, X-ray 
crystallography and nuclear magnetic resonance (NMR) spectroscopy offer the 
highest degree of structural information.  Crystallographers obtain an electron 
density map from the X-ray diffraction of highly ordered crystals, which is then used 
to build a model structure of the protein, whose sequence has been determined by 
other means.65  In NMR spectroscopy, the nuclear Overhauser effect between 
different nuclear spins is used to identify hydrogen atoms in proximity to each other, 
either due to primary structure or as a result of the protein’s three-dimensional fold.66  
This yields a series of constraints to the possible distances and angles between atoms, 
from which a model can be constructed. 
Both techniques offer unparalleled structural resolution and NMR spectroscopy has 
the additional advantage of being able study proteins in their ‘natural state’, in 
solution.  However, each method also has its drawbacks.67  Both require a relatively 
large quantity of protein: typically ~1 mM solutions for NMR.  The resolution of X-
ray diffraction data is highly dependent on the formation of well ordered crystals and 
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some proteins are particularly resistant to crystallisation.  In addition, the static 
nature of crystallography is not applicable to the measurement of dynamic processes.  
NMR is routinely used to monitor such processes, but spectra reveal only the average 
state of a protein complex. 
1.4.2 Circular dichroism and other spectroscopies 
In addition to the techniques described above, a range of low-resolution 
spectroscopic methods are available for the study of peptide structure, including: 
infrared,68 fluorescence,69 Raman70 and circular dichroism (CD)71 spectroscopies.  
Whilst none of these techniques provides the same level of detail as NMR or X-ray 
crystallography, they can be useful in identifying changes in protein structure that 
occur in response to an external stimulus.72 
CD spectroscopy has the advantage of being relatively simple to perform and is used 
in this thesis as a probe of secondary structure.  Circular dichroism is the differential 
absorption of left and right circularly polarised light and is observed when a 
chromophore is chiral – either intrinsically or as a result of its three-dimensional 
environment within the molecule.71  The peptide bond is a UV chromophore with a 
weak, n→* transition at ~220 nm and a more intense →* transition at ~190 nm.  
In proteins, the distinct environments created by different types of secondary 
structure result in different CD signals.  Given that these absorptions are broad and 
proteins generally contain a mix of structural elements, exact quantification of the 
structural composition from the CD spectrum is difficult.  Instead, an estimation of 
the secondary structure content can be obtained by using various algorithms that 
compare the CD spectrum to those whose structure has been solved by 
crystallography.73 
1.4.3 Mass spectrometry 
Principles 
Mass spectrometry (MS) is a powerful tool for the study of protein and peptide 
structure because of its sensitivity, speed and specificity.67, 74-77  The ability to gain 
useful structural information from a few picomoles of an analyte is a major 
advantage where the molecule of interest is particularly valuable or in short supply. 
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Furthermore, MS can be used to examine dynamic mixtures and so complements 
higher resolution techniques such as NMR and crystallography, which are not suited 
to such analyses. 
Mass spectrometry involves the measurement of gaseous ions according to their 
mass-to-charge ratio (m/z).  As such, in an MS experiment there is a requirement for: 
(i) the conversion of solution-phase molecules to gas-phase ions; (ii) the separation 
of these ions based on their m/z; and (iii) the recording of the separated ions.  These 
functions are carried out respectively by the ion source, the mass analyser and the 
detector of the mass spectrometer.  
Ionisation 
Ionisation is the critical step in preserving a conformation in the gas-phase that is 
representative of the protein’s structure in solution and is discussed below.  Mass 
analysers and detectors are described only briefly in this thesis but a more thorough 
explanation of their operation can be found in references (78) and (79). 
In the field of protein mass spectrometry, currently the two most commonly 
employed methods of ionisation are electrospray ionisation (ESI)80, 81 and matrix-
assisted laser desorption/ionisation (MALDI).82, 83  These ionisation techniques have 
found widespread application because in each case the ionisation process occurs with 
minimal fragmentation of the analyte in the ion source.  In MALDI, the protein 
sample is generally co-crystallised with an organic acid.  Consequently, MALDI is 
generally less suited to the study of natively-folded proteins and complexes since the 
low pH can result in denaturation.  In this thesis only ESI will be discussed. 
In ESI, the sample is delivered through a metal capillary to which a high electric 
potential is applied.  Either positive or negative ions can be generated; the applied 
potential generally being of the order of ± 2 to 5 kV.  In the case of positive ion 
formation, the positively-charged particles are drawn towards the end of the capillary 
to form a so-called Taylor cone,84, 85 from which a fine spray of highly charged 
droplets is produced (Figure 1.6).  
16 
 
Figure 1.6 Mechanism of electrospray ionisation 
 
Illustration of Taylor cone formation and subsequent desolvation to gaseous ions, adapted 
from ref (85).  Note that the source shown above is a nano-electrospray ionisation source 
(see page 17). 
Evaporation of the solvent, facilitated by heat and the flow of a nebulising gas, leads 
to a decrease in the size of the droplets and an increase in the density of charge at the 
surface.  Eventually the Coulombic repulsion between like charges at the surface 
becomes sufficiently large so as to overcome surface tension and cause fission of the 
droplet.  This process continues, producing sequentially smaller droplets until a 
desolvated ion is formed.  Decreasing potential and pressure gradients, from the tip 
of the capillary to the interface with the mass analyser, propel the ions into the 
spectrometer. 
The mechanism of the final step in which a solvent-free ion is formed from a charged 
droplet has been the subject of much debate.  There are two major theories: the 
charged residue model, proposed by Dole,80 and the ion evaporation model, put 
forward by Iribarne and Thomson.86  In the former model, droplet fission (as 
described above) continues until a single analyte ion remains within a droplet.  Total 
desolvation of this droplet leaves the gaseous “charged residue”.  The latter (ion 
evaporation) model states that, before complete evaporation of the solvent occurs, the 
analyte ion is expelled from the droplet when Coulombic repulsion exceeds the 
forces of solvation.   Whilst it appears that the majority of ions are not formed 
exclusively by a single mechanism, there is evidence to support the premise that 




During the electrospray ionisation of large molecules, multiply-charged analyte 
species are created.  In the positive ionisation of proteins, this often corresponds to 
the addition of a proton (or another positive ion, such as Na+) to some or all of the 
basic amino acid side-chains within the molecule.  Given that, in MS, it is the mass-
to-charge ratio that is measured, this inherent feature of ESI means that even very 
large molecules can be detected within the range of common mass analysers (m/z = 
100 – 2000). 
Although various different solvents can be used in ESI-MS, ESI is most efficient 
when volatile, protic co-solvents such as methanol are used.  ESI of samples in 
aqueous solution is possible and is routinely performed for the study of natively 
folded proteins but the comparatively low vapour pressure of water means that 
sensitivity is reduced.  Volatile buffers such as ammonium acetate are preferred to 
those which are less volatile such sodium and potassium phosphate for the reasons 
discussed above. 
The ESI process was improved by Wilm and Mann with the development of nano-
electrospray ionisation (nESI).88  Similar to ESI, ions are formed by a sequential 
fission of charged droplets as described previously, however a finely-tipped glass 
capillary with a micron-wide internal diameter is used in nESI rather than the metal 
capillary (i.d. ~ 0.1 mm) employed in ESI.  In nESI, the voltage (± 1 to 2 kV) is 
applied either to a metal coating on the inside of the glass capillary, or to an inert 
metal wire inserted into the sample solution.  The result is that the droplets formed 
by nESI are an order of magnitude smaller than those generated in conventional 
ESI.89, 90 
The low flow rates utilised in nESI (~20 nl/min, compared to 1-1000 l/min in ESI) 
have the advantage of decreased sample consumption as well as improved sensitivity 
since the smaller droplet size means that salts and other impurities, which are 
detrimental to ionisation of the analyte, are less concentrated.  An excellent example 
of this is described by Benesch et al., who observed a remarkable improvement in 
the resolution of an 800 kDa tetradecameric complex when nESI was used rather 
than conventional ESI (Figure 1.7).77  Since less energy is required for the 
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desolvation of smaller droplets, some protein ions formed by nESI may be more 
‘native-like’ than those produced by ESI. 
Figure 1.7 Comparison of nESI and ESI spectra for the GroEL14 complex 
 
The upper spectrum, obtained using nESI, shows excellent resolution of the 14-mer.  The 
lower (ESI) spectrum shows poor resolution and non-specific oligomerisation.  Image taken 
from reference (77). 
Mass analysis and detection 
This thesis employs a Q-ToF mass spectrometer, featuring quadrupole (Q) and time-
of-flight (ToF) mass analysers, which are introduced below.  A more detailed 
description of these and other types of mass analyser can be found elsewhere, 
including references (78) and (79). 
A quadrupole comprises four parallel rods, with opposite rods paired electronically.91  
An alternating RF potential plus a fixed DC voltage are applied to the rods such that 
when one pair of rods is in-phase (e.g. positive) the other pair is completely out of 
phase (i.e. negative).  The total electric field experienced by ions passing through the 





{ 1.1 }  tVU cos0   and  tVU cos0   
where is the total potential on the rods, U is the DC potential, V is the peak 
amplitude of the RF potential and  is the angular frequency (equal to 2v, where v 
is the RF frequency).  Upon entering the quadrupole, a positively-charged ion will be 
attracted towards a negative rod.  As shown in equation {1.1}, the potential on this 
rod is a cosine function of time, t.  Thus, the trajectory of the ion will change if the 
potential changes sign before the ion collides with the rod. 
Ions of a given m/z have certain values of U, V and that generate a stable trajectory 
for transmission (Figure 1.8).  Ions of different m/z values can be transmitted by 
scanning the RF amplitude: upon detection, a mass spectrum can be generated by 
determining the m/z from the detection time and the potential applied.  Alternatively, 
the quadrupole can be used as a mass filter, whereby only ions of a particular m/z 
range are transmitted.  This method of operation is commonly employed when the 
quadrupole is used in tandem with other mass analysers. 
Figure 1.8 Quadrupole mass analyser 
 
Opposite rods have the same sign, adjacent rods have the opposite sign.  The red ion has a 
stable trajectory and is transmitted, the blue ion has an unstable trajectory and is discharged 
as it collides with the rod.  Image adapted from ref (92). 
In the time-of-flight mass analyser, packets of ions are accelerated by a potential (V) 
into a field-free drift tube.93  As shown in equations {1.2} to {1.4}, the time taken for 
an ion to travel a fixed distance (d) is related to its m/z: 
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where Ek is kinetic energy, q is charge and e is the charge on an electron. 
The mass resolution of ToF analysers is improved by the use a reflectron.94 A 
reflectron is a series of grids and ring electrodes that creates a retarding field, 
deflecting the ions back along the drift tube.  In addition to increasing the effective 
drift length, the reflectron refocuses ions of the same m/z that have small differences 
in kinetic energy (Figure 1.9). 
Figure 1.9 Schematic of a ToF analyser equipped with a reflectron 
 
Ions of the same m/z but greater kinetic energy penetrate the retarding field of the reflectron 
more deeply.  Thus more energetic ions spend longer in the reflectron and ultimately arrive 
at the detector at the same time as less energetic ions. 
ToF instruments commonly use microchannel plate detectors.78  These contain an 
array of electron multiplier channels, each coated with a semiconductor.  An ion 
entering a channel will strike the semiconductor surface, releasing secondary 
electrons.  This process continues, creating a cascade of electrons that are then 
measured as a current. 
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Relevance of gas-phase measurements to protein studies 
A major issue surrounding the analysis of proteins by mass spectrometry is the extent 
to which the gas-phase structures of proteins resemble their solution-phase 
counterparts.95  Clearly there must be some correlation with the situation in vivo for a 
mass spectrometry experiment to be of relevance in a biological context. 
Modern ionisation techniques such as ESI, allow specific, non-covalent interactions 
to be preserved without molecular fragmentation.  As a result, a multitude of non-
covalent protein complexes have been observed with MS, including enzyme-
substrate,96 receptor-ligand,97 antibody-antigen98 and protein-protein (i.e. quaternary 
structure) aggregates.76, 77, 99, 100  An elegant illustration of the use of ESI-MS to 
determine the stoichiometry of the constituent parts of a protein complex is described 
by Medalia et al.101  Analysis of a nucleotidase by size-exclusion chromatography 
implied that the enzyme had a molecular mass of around 600 kDa and therefore 
existed as a dodecameric complex.  However, the ESI-MS spectrum indicated the 
presence of hexamer, not a dodecamer.  The MS data was validated by electron 
microscopy which confirmed that the complex was a hexamer containing a large 
cavity.  The hollow space gives the complex results in an unusually large diameter 
and so the protein exhibits a deceptively short elution time in size-exclusion 
chromatography. 
When considering likely protein conformations, it is worth noting that the energy of 
a particular protein fold is partly dependent on the non-bonded interactions within 
the molecule.102  Protein folding is typically driven by a combination of the 
following non-covalent interactions: hydrogen bonding, van der Waals forces, 
electrostatic interactions and the hydrophobic effect.  Given that in the mass 
spectrometer there is no solvent with which the protein complex can interact, it is 
likely that ionic interactions become reinforced upon transfer of the protein complex 
to the gas-phase.  For instance, the binding of an acidic peptide to a (basic) 
polyamine is much stronger in the gas-phase than in solution.103  Conversely, the 
strength of hydrophobic interactions diminishes when removed from the solvent.  For 
example, Robinson et al. observed that various protein-coenzyme complexes had 
different solution-phase dissociation constants but similar gas-phase stabilities.103, 104 
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One variable in the estimation of the energy of these interactions is the dielectric 
constant of the medium, o.  It has been calculated that proteins typically have o 
values in the range 2-6.105  The dielectric constant of water is 78,106 whereas that of a 
vacuum is 1 by definition.  Thus, in this regard the immediate environment of a 
cellular protein, especially those which are in the vicinity of membranes, can be said 
to be better represented by the gas-phase than by dilute aqueous solution. 
The single most important factor which affects a protein’s gas-phase structure is that 
of its solution-phase conformation prior to ionisation.107, 108  ESI mass spectra of 
denatured proteins tend to exhibit more highly charged species than those of natively 
folded species (Figure 1.10).  In addition, a broader distribution of charge states may 
be observed for denatured proteins.  This is partly as a result of the increased number 
of basic sites which become available for protonation when a protein is unfolded.  
Accordingly, ESI-MS can be used to evaluate the degree to which a protein is folded 
in solution. 












ESI mass spectra of a 10 mM solution of lysozyme in (a) 10 mM ammonium acetate buffer 
and (b) 49.5% water, 49.5% methanol, 1.0% formic acid.  Ions of lower charge are observed 
for the buffered protein solution, indicating that the addition of acid and organic solvent 
denatures the protein to some extent.  Spectra were acquired on an LCQ Classic (Finnigan). 
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Perhaps one of the most attractive features of mass spectrometry is its ability to be 
used in combination with other methods of analysis.  In this way, it is possible to 
gain a greater degree of structural information than would be possible from MS 
alone.  Discussed below is the utility of the mass spectrometer as a detector for ion 
mobility spectrometry, which is a useful technique for probing the tertiary structures 
of proteins in the gas-phase. 
1.4.4 Ion mobility-mass spectrometry 
Ion mobility spectrometry (IMS) is the separation of gaseous ions on the basis of 
their charge and average size.109-111  A variety of different IMS set-ups exist112, 113: 
the only method that allows the direct calculation of the size of an ion is known as 
drift-time IMS and this method is used in this thesis.  Other commonly employed 
IMS methods include travelling-wave IMS (TWIMS) and field-asymmetric 
waveform IMS (FAIMS). 
Drift-time IMS 
In a drift-time IMS experiment, pulses of gaseous ions are introduced to a drift cell 
containing an inert buffer gas and to which a uniform electric field is applied.  The 
ions are accelerated through the cell by the potential gradient, but decelerated by 
collisions with the buffer gas.  Thus, the ions traverse the cell with a constant drift 
velocity, vD, which is determined by measuring the drift time.  The mobility (K) of an 
ion is defined as the ratio of its drift velocity (vd) to the electric field strength (E): 
{ 1.5 } 
E
v
K d  
The energy of an ion in such a system is given by the electric field strength divided 
by the number density of the buffer gas, N.  When operating in the so-called ‘low-
field limit’ (i.e. below ~10 Td, where 1 Td = 10-17 V cm2) there is no alignment of 
the ions in the electric field and vd is independent of E.  Under these conditions, the 
mobility of the ion can be described by:114  
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Where  is the reduced mass of the analyte and the buffer gas, kB is the Boltzmann 
constant, T is the temperature in Kelvin and  is the momentum transfer integral 
(effectively the rotationally-averaged collision cross-section: a measure of the size 
and shape of the ion).  For ease of comparison, often mobility is quoted in terms of 
the reduced mobility, Ko, which accounts for experimental variances in temperature 
and pressure: 




















where P° and T° are the standard pressure (760 Torr) and temperature (273.15 K) 
respectively. 
As shown in equation {1.6}, the mobility of an ion is inversely related to its 
rotationally-averaged collision cross-section.  In other words, a more compact ion 
will undergo fewer collisions with the buffer gas and hence travels faster through the 
drift cell than a more extended ion (Figure 1.11).  This phenomenon can therefore be 
used to separate ions of the same m/z but of different conformations: for example a 
folded protein versus a denatured protein.115, 116 
Figure 1.11 Separation of protein conformations by drift-time IMS 
 
In this schematic, two ions of the same mass and charge are resolved by IMS.  In (a) the 
more extended (blue) protein conformer takes longer to traverse the drift cell because it 
collides more often with the buffer gas than the compact (red) protein conformer.  This gives 
rise to the arrival time distribution (b).  Graphic based on that from ref (77). 
Ion mobility spectrometry and mass spectrometry are extremely complementary 
given that both methods involve the analysis of gas-phase ions.  IMS drift times are 





versus s) and so it is possible to ‘nest’ mass spectra within ion mobility spectra.117-
119  Combination of the two techniques (IM-MS) allows for the separation of ions 
firstly on the basis of their size/charge and then according to their mass/charge. 
 
TWIMS 
Travelling-wave IMS is a different mode of ion mobility separation that has been 
successfully integrated into a commercially available IM-MS instrument.120  
Separation occurs in one of three stacked ring ion guides (the others being used for 
the accumulation and transfer of ions).  The ion guide consists of a sequence of ring 
electrodes, ordered so that opposite phases of an RF voltage are applied to 
neighbouring electrodes.121  A sequence of transient DC voltages applied to adjacent 
electrodes generates a ‘travelling wave’ for the propulsion of ions through the 
apparatus (Figure 1.12).  Although the net movement of ions is in the direction of the 
wave, frictional forces at typical operating pressures (> 0.2 mbar) result in ions 
periodically slipping behind the wavefront. 
Since ions of greater mobility fall behind the wave less often than those of lesser 
mobility, separation of ions on the basis of their mobility results.  Unlike drift-time 
IMS, in TWIMS the drift time of the ion is not directly proportional to its collision 
cross-section.122  To derive this information from TWIMS data, a calibration of drift 
time to cross-section is performed using standards whose cross-section has been 
determined by drift-time IMS previously.123  For accurate results, this approach 
requires a calibration set that encompasses the size of the analyte of interest.  
Furthermore, in the case of proteins and peptides, it is important that the ‘standard’ 
proteins exhibit the same conformations in both drift time and TWIMS instruments. 
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Image based on that given in reference (120). 
FAIMS 
Also referred to as differential mobility spectrometry, field-asymmetric waveform 
IMS represents an alternative technique for the separation of ions on the basis of 
their mobility.124, 125  In FAIMS ions pass between two electrodes, which are either 
planar and parallel or cylindrical and concentric.  An alternating electric field, 
perpendicular to the gas flow, is applied such that the ions oscillate between the two 
electrodes and disperse according to their difference in mobilities (Figure 1.13).  
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Superimposition of a DC ‘compensation voltage’ allows ions to traverse the device: 
scanning this voltage allows ions of varying mobility to be detected. 










(a) The field applied is twice as strong in one direction as the in the other but is applied for 
only half as long.  (b) The red ion has higher mobility at low field than high field and so it 
moves towards and collides with the bottom electrode.  The blue ion has higher mobility at 
high field and so strikes the top electrode.  The mobility of the green ion in high and low 
fields is balanced such that the net displacement from the centre is zero and so is 
transmitted.  Image modified from reference (125). 
Unlike drift-time IMS, a high electric field is used and so mobility (and therefore 
collision cross-section) is not independent of electric field strength.  In some cases, 
the heating of ions in high electric fields can induce protein unfolding.126  
Nonetheless, FAIMS has proven to be useful in the separation of complex biological 
mixtures.127, 128 
Applications 
Particularly in recent years with the advent of commercially available ion mobility-
mass spectrometers,120, 129 an increasing number of researchers are using IM-MS in 
the study of biomolecules.130  IM-MS can provide useful insights into protein 
28 
 
structure, especially when analysis by traditional methods is problematic.  Examples 
include the investigation of large, multi-protein complexes,123, 131 and the analysis of 
dynamic mixtures of proteins that aggregate.132-134  
In a study in 2007, Ashcroft and co-workers used IM-MS to investigate the structure 
of 2-microglobulin, a peptide known to form amyloid fibrils.135  They reported that 
a greater percentage of a mutant was in a more unfolded conformation when 
compared to the unmodified peptide, as indicated by its greater collisional cross-
section.  Since fibril formation is a result of protein misfolding, the authors propose 
that this may explain the increased amyloidogenicity of the mutant. 
In another example, Heck and colleagues presented interesting IM-MS data in their 
study of PKG, a protein kinase activated by the binding of cyclic guanosine 
monophosphate (cGMP).136  Although the crystal structure of this enzyme has yet to 
be reported, it is believed that PKG expands upon activation by cGMP.  Two aspects 
of the IM-MS data support this theory.  First, comparison of the ESI mass spectra of 
PKG before and after binding of cGMP shows that the charge state distribution of the 
activated complex is centred around a higher charge, relative to that of the free PKG.  
This suggests that, as cGMP binds to PKG, the conformation of PKG changes such 
that more residues are available for protonation in ESI.  Second, the drift times of 
each cGMP-bound PKG ion are longer than those of the cGMP-free ions of the same 
charge state, indicating that the activated PKG complex has a more extended 
structure.  Together, the MS and ion mobility data confirm that PKG adopts a more 
open conformation when bound to cGMP. 
Evaluation of ion mobility data 
Ion mobility data can be compared to those from other techniques by calculating the 
theoretical collision cross-section of a protein structure obtained by molecular 
modelling, NMR spectroscopy or X-ray crystallography.  Structures obtained by the 
latter two methods are available from an online repository known as the Protein Data 
Bank (PDB), run by the Research Collaboratory for Structural Bioinformatics.137  
There are three different methods of calculating the rotationally-averaged collision 
cross-section: the projection approximation (PA), the exact hard-sphere scattering 
(EHSS) model and the trajectory method (TM). 
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In the projection approximation the average cross-section is calculated for each 
possible orientation of the molecule, with each atom within the molecule assumed to 
be a hard-sphere.  In the original iteration of the PA, the interaction between the ion 
and the buffer gas was considered simply as a hard-sphere collision.138  This model 
was improved by von Helden et al., who allowed for the variation in atomic radii 
with temperature.139 
The PA only holds for molecular surfaces that are perfectly convex.  In reality, the 
irregular surface of a protein molecule means that multiple collisions may occur at 
some regions, whilst parts of the molecule may be protected from collisions by 
another.  This lead to the development of the EHSS model by Shvartsburg and 
Jarrold to account for such phenomena.140  A further refinement, known as the 
trajectory method, also considers long-range interactions between the ion and the 
buffer gas.141 
In their 1997 review, Clemmer and Jarrold compared these various methods.109  They 
demonstrated that for molecules of >200 atoms, the PA significantly underestimates 
the collision cross-section, whilst the EHSS and TM values are similar.  For bovine 
pancreatic trypsin inhibitor (a peptide of similar size to defensins), the cross-section 
obtained by the PA was ~17% smaller than the EHSS and TM values; for larger 
molecules this deviation increases.  The EHSS and TM methods are therefore the most 
suitable for calculating the collision cross-sections of biomolecules. 
1.5 Summary 
In this thesis, ion mobility-mass spectrometry is employed to examine the 
conformations of β-defensins.  Structure-activity relationships of the murine β-
defensin Defb14 are interrogated using a sequence modification approach.  In 
addition, the interactions of human β-defensins 2 and 3 with oligosaccharides are 
studied.  It is hoped that a greater understanding of the structures of β-defensins, and 
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2.1 Mass Spectrometry 
All of the mass spectra presented in this thesis were obtained using a quadrupole 
time-of-flight mass spectrometer with nano-electrospray ionisation. 
2.1.1 Nano-electrospray ionisation 
Peptide solutions were prepared at a concentration of 20-100 M.  Various solvent 
conditions were used: these are discussed in more detail in the relevant chapters.  
Buffered solutions at ‘near-native’ pH 6.8 were prepared using 10-20 mM 
ammonium acetate (Sigma Aldrich, Gillingham, UK).  Denaturing solutions were 
prepared using 49.5% water, 49.5% methanol, 1.0% formic acid.  High purity water 
was obtained from an Arium 611 water purification unit (Sartorius, Göttingen, 
Germany) fitted with a 0.2 m filter.  Solvents were obtained from Fisher Scientific 
(Loughborough, UK). 
Nano-electrospray tips were made in-house from thin-walled glass capillaries (i.d. 
0.5 mm, Precision Instruments, Stevenage, UK) using a Flaming/Brown micropipette 
puller (Sutter Instrument Company, Novato, CA, USA).  These were then filled with 
sample using gel micro-loading tips (Eppendorf, Hamburg, Germany).  A positive 
voltage (1.4-2.2 kV) was applied to the solution via a platinum wire inserted into the 
capillary.  The spray voltage used depended largely on the solvent composition: 
typically ~1.8 kV was required. 
2.1.2 Ion transfer, mass analysis and detection 
In addition to the ion mobility-mass spectrometer described in section 2.2, mass 
spectra were recorded on the Q-ToF II (Waters, Manchester, UK) (Figure 2.1).  
Ions generated by nESI enter the mass spectrometer via a ‘Z-spray’ source.  In this 
arrangement, the axis of the sample capillary is orthogonal to the sampling orifice 
(the cone), which is in turn perpendicular to the following lens element (the 





whilst limiting the transfer of neutral species.  For each experiment in this work, the 
temperature of the source region was set to 80 °C to aid desolvation.   
Figure 2.1 Waters Quadrupole Time of Flight (Q-ToF) mass spectrometer 
 






Shown are: (a) nESI capillary; (b) cone; (c) extractor; (d) transfer hexapoles; (e) quadrupole 
analyser; (f) collision cell; (g) pusher; (h) reflectron; (i) multichannel plate detector.  The three 
differential pumping regions are indicated as source, analyser and ToF. 
After passing through the extractor, the ions are guided through a transfer hexapole 
to the quadrupole analyser.  Collision-induced dissociation can be performed by 
using the quadrupole to select ions of a particular m/z and then increasing the kinetic 
energy of these ions as they enter the collision cell.  However, for all experiments in 
this thesis, the quadrupole was used simply as a mass filter and the ions were not 
subjected to fragmentation inside the collision cell. 
The ions are analysed subsequently by time-of-flight mass spectrometry, where the 
velocity of each ion is inversely proportional to its m/z.  The ions are pulsed down 





focused and reflected towards the microchannel plate detector.  The signals from the 
ions arriving at the detector pass through a 4 GHz time-to-digital converter and are 
processed into mass spectra by MassLynx software (version 4.1, Waters, 
Manchester, UK). 
The mass spectrometer contains three differential pumping regions: the source, 
quadrupole analyser and ToF chambers.  Each chamber is pumped by a 
turbomolecular pump, backed by a rotary pump.  On the Q-ToF II, typical pressures 
in each region are as follows: source ~ 1.7 mbar; analyser ~ 2.4 x 10-5 mbar; ToF ~ 
4.4 x 10-7 mbar. 
External mass calibration was performed prior to sample analysis.  Sodium iodide 
clusters were used as a reference, using a 2 mg/ml solution of NaI in 50% water, 
50% isopropanol. 
2.2 Ion mobility-mass spectrometry 
Samples for IM-MS were prepared and ionised by nano-electrospray as described in 
section 2.1.1. 
2.2.1 Instrument description: the MoQToF 
Ion mobility measurements were made on the ‘MoQToF’ (mobility quadrupole time-
of-flight) instrument.  This is a Q-ToF mass spectrometer, similar to that described 
above, that has been customised to include a 5.1 cm copper drift cell for ion mobility 
spectrometry.1  The drift cell is filled with helium as a buffer gas and is situated 
between the first transfer hexapole and the quadrupole analyser, as shown in Figure 
2.2.  The instrument can be used for both mass spectrometry and ion mobility-mass 
spectrometry.  In MS mode, a continuous beam of ions is allowed to pass through the 
drift cell.  In IM-MS operation, ions are pulsed through the drift cell to allow for 
separation based on their mobility.   
In addition to the differential pumping regions present in the QToF II mass 
spectrometer, the MoQToF contains an additional vacuum chamber that houses the 





pump.  On the MoQToF, typical pressures in each region are: source ~ 0.5 mbar; 
drift chamber ~ 1.3 x 10-3 mbar; analyser ~ 3.0 x 10-6  mbar; ToF ~ 1.0 x 10-7 mbar. 






Highlighted are: (a) pre-cell hexapole; (b) top hat lens; (c) drift cell; (d) post-cell hexapole. 
Note the presence of an additional differential pumping region – the drift chamber. 
During each IM-MS experiment, ions are accumulated in the pre-cell region as a 
result of a raised potential on the ‘top hat’, the lens element immediately prior to the 
entrance lenses of the drift cell.  At regular intervals, this trapping voltage is lowered 
for 40 s to inject a pulse of ions into the drift cell.  The frequency of this pulse is set 
using a signal generator (Stanford Research Systems, Sunnyvale, CA, USA) and is 
dependent on the ToF pusher period.  Typically, a pusher period of 90 s is used to 





exiting the drift cell, the ions pass via a short re-focusing lens through a second 
hexapole and from that into a Q-ToF mass spectrometer. 
Ion arrival time distributions (mobility spectra) are recorded by synchronisation of 
the release of ions into the drift cell with mass spectral acquisition.  The cell contains 
helium (99.999%, BOC Speciality Gases) at a pressure of 3.0-3.8 Torr and a 
temperature of 37 ± 5 °C.  For all experiments, the injection energy (the potential 
difference between the first transfer hexapole and the drift cell) was between 34 and 
39 V.  Within an acquisition, the pressure in the cell does not drift by more than 0.01 
Torr and for each experiment the temperature of the drift cell does not vary by more 
than 3 °C.  Ion mobility measurements of ‘standard’ proteins on this instrument 
compare favourably with literature values.1 
2.2.2 Data acquisition and analysis: an example 
The following experiment is provided as an example of the procedure for acquiring 
IM-MS data and as a proof of concept.  Two linear peptides and two cyclic peptides, 
shown in Figure 2.3, were analysed by ion mobility-mass spectrometry.  Each 
peptide was prepared at 50 M in 0.01% formic acid and ionised by nESI as 
described in section 2.1.1. 






The linear peptides (L1 and L2) have an amide group at the C-terminus.  In the cyclic 
peptides (C1 and C2), the ‘termini’ are connected via an intramolecular amide bond.  ‘C(Am)’ 
denotes a cysteine in which the thiol group is protected by an acetamide group. 
Data acquisition 
In IM-MS mode, a total arrival time distribution (ATD), corresponding to one 
mobility separation, is generated once every 200 MS scans.  Spectra were acquired 
for a minimum of ten pulses (i.e. 2000 MS scans) per drift voltage (Figure 2.4) and 
summed.  Initially the drift voltage (i.e. the electric potential difference across the 
L1:     CRKFFARIRGC-NH2 







cell) was set to 60 V.  The process was repeated at eight further drift voltages: 50, 40, 
35, 30, 25, 20, 15 and 10 V.  Pressure and temperature were recorded for every 
measurement taken. 














Each pulse corresponds to 200 MS scans. 
Data analysis 
A mass spectrum (Figure 2.5) was generated from the total ATD using the MassLynx 
software.  This shows the m/z of each species arriving at the detector across the entire 
range of arrival time.  For each peptide, three charge states [M+zH]z+ were observed, 
with z = 2-4.  The software allows the arrival time distribution of each separate ion to 
be reconstructed (Figure 2.6).  The average scan number was calculated in Origin 8.0 
(OriginLab, Northampton, MA, USA) by fitting a Gaussian distribution and 
determining the midpoint (Figure 2.7).  Multiplication of the average scan number by 
the MS pusher period gives the average arrival time.  This was performed for the 
ATD of every ion at each drift voltage. 







































Shown are: (a) total ATD; (b) reconstructed ATDs for the 2+, 3+ and 4+ charge states. 
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For each ion, the arrival time (ta) comprises the time taken to traverse the drift cell 
(the drift time, td) plus the time taken to reach the detector upon exiting the drift cell 
(the dead time, t0).  The dead time can be obtained from a plot of the arrival time 
versus the ratio of pressure to drift voltage (Figure 2.8, y = t0 at x = 0).  As expected, 
the arrival time increases with increasing P/V.  The good linear fit of these data 
indicates that, as required, the experiment was conducted within the low-field limit, 
that is to say that there was no alignment of the ions in the electric field and the drift 
time is directly proportional to the rotationally-averaged collision cross-section. 
The gradient of this line is inversely proportional to the reduced mobility (Ko) of the 
ion (equation {2.1}).  The rotationally-averaged collision cross-section () can then 
be calculated from Ko (equation {2.2}).  Each complete IM-MS experiment was 
performed in triplicate and the mean collision cross-section calculated for each 
charge state. 
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Where L is the length of the drift tube, Ko is reduced mobility, V is the drift voltage, 





















Where  is the rotationally-averaged collision cross-section (strictly, the momentum 
transfer integral), N is the number density of the buffer gas, is the reduced mass of 
the analyte and the buffer gas, kB is the Boltzmann constant.  
Figure 2.8 Plot of arrival time versus P/V for peptide L2 [M+2H]2+ ion 
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Results and discussion 
The rotationally-averaged collision cross-sections for each of the linear and cyclic 
peptides are shown (Table 2.1). 
Table 2.1 Mean collision cross-sections of the linear and cyclic peptides 
 Collision cross-section (Å2) a 
Peptide L1 L2 C1 C2 
[M+2H]2+ 316 ± 4 319 ± 2 288 ± 6 295 ± 7 
[M+3H]3+ 324 ± 7 320 ± 6 282 ± 5 296 ± 5 
[M+4H]4+ 349 b 365 b 298 b 306 b 
a Uncertainties are quoted as the standard deviation. 
b The [M+4H]4+ charge state was observed with significant intensity in one run only. 
It might be expected that the cyclic peptides would present more compact 
conformations than the linear peptides.2  From the IM-MS data, it can be seen that 
this is indeed the case.  For each charge state, the cyclic peptide has a smaller cross-
section than its linear precursor.  Comparison of L1 and C2, which each have 11 
amino acids, shows that this is not solely attributable to a difference in chain length.  
Instead the difference in cross-section results from the more extended structure of 
linear peptide, relative to the cyclic peptide. 
Further evidence of the difference in conformation can be obtained by considering 
the change in collision cross-section with increasing charge state of a given peptide.  
For the linear peptides,  increases with increasing positive charge.  At higher 
charge states, the L1 and L2 are able to adopt more extended conformations to 
minimise Coulombic repulsion.  For example, the [M+4H]4+ ion of L2 has a collision 
cross-section 14% greater than the [M+2H]2+ ion.  In contrast, the ‘termini’ of the 
cyclic peptides are joined by a covalent bond, which constrains their three-
dimensional structure.  As a result, they cannot unfold to the same extent: the 
difference between the 4+ and 2+ charge states of C2 is 4%, which is within two 
standard deviations. 
Thus in this example it has been demonstrated that IM-MS can be used to separate 





2.2.3 Estimation of collision cross-sections from PDB structures 
The program Mobcal3, 4 provides algorithms for calculating the momentum transfer 
integral,  (i.e. collision cross-section).  This was used to estimate the collision 
cross-sections of NMR and X-ray crystal structures of proteins/peptides provided in 
the protein databank, as well as theoretical models.  Three methods are available in 
Mobcal: the projection approximation (PA), the exact hard-sphere scattering model 
(EHSS) and the trajectory method (TM).  As discussed in Chapter 1, the PA 
approach underestimates  and so only the EHSS or TM values are reported in this 
thesis. 
2.3 Homology modelling 
In cases where a suitable template structure exists, homology modelling can be a 
useful tool to generate a three-dimensional model of a protein whose structure has 
yet to be characterised experimentally.5  Homology modelling, where employed, was 
performed by utilising the alignment mode of the SWISS-MODEL homology 
modelling server.6  Explicit hydrogens were then added to the model using the Leap 
application, which is contained in the Amber 9 suite of programs.7  Finally, a limited 
energy minimisation was performed by relaxing strained bonds, angles, and torsions: 
no additional optimisation of geometry was carried out. 
2.4 Liquid chromatography-mass spectrometry 
Reversed-phase high performance liquid chromatography-mass spectrometry 
(HPLC-MS) was employed to evaluate the relative molecular hydrophobicity of 
peptides.  An Ultimate 3000 LC system (Dionex, Camberley, UK), coupled to a VG 
Platform II mass spectrometer, was used.  The HPLC system was equipped with a 
Famos autosampler (Dionex). 
30 l of each sample, containing 50 M peptide and 50 M melittin (Sigma-Aldrich, 
Gillingham, UK) as an internal standard, was injected onto a Waters Symmetry C18 
column (3.9 x 150 mm).  Samples were prepared both in water and in 10 mM 





cysteine oxidation and this was confirmed by mass analysis following the HPLC 
separation. 
High purity water was obtained from an Arium 611 water purification unit (Satorius, 
Göttingen, Germany) fitted with a 0.2 m filter.  Solvents were obtained from Fisher 
Scientific (Loughborough, UK).  Initial buffer conditions were as follows: 100% 
eluent A (96% water, 3% acetonitrile, 1% formic acid); 0% eluent B (4% water, 95% 
acetonitrile, 1% formic acid); flow rate 1 ml min-1.  These conditions were held for 3 
minutes before commencing a linear gradient of 0 – 40% eluent B over 40 minutes to 
elute the samples from the column.  The flow was split 1/50 prior to introduction to 
the electrospray ionisation source of the mass spectrometer. 
2.5 Circular dichroism spectroscopy 
The secondary structure content of peptides was probed by circular dichroism 
spectroscopy.  Peptide solutions were prepared at an approximate concentration of 
200 g/ml in: (i) 10 mM ammonium acetate, pH 6.8, and (ii) 50% water, 50% 2,2,2-
trifluoroethanol (TFE).  Samples were placed in quartz cuvette (Hellma, Essex, UK) 
of pathlength 1 mm.  CD spectra were recorded over the range 190 – 260 nm at 20 
°C using a J-810 spectropolarimeter (Jasco, Essex, UK).  Five scans were acquired 
for each sample at a rate of 10 nm min-1 and averaged to give a final sample 
spectrum.  A blank spectrum, acquired in the absence of peptide in precisely the 
same way, was subtracted from each final sample spectrum.  The concentration of 
each peptide solution was determined subsequently by assaying with bicinchoninic 
acid8 (Pierce) and the mean residue ellipticity was calculated at each wavelength.  
The CDSSTR algorithm9 on the DICROWEB server10 was used to help assign 
secondary structure. 
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3 Chemically modified single-cysteine derivatives of Defb14 
 
The understanding of how β-defensin structures are related to their functions was 
complicated by the discovery of a peptide that was fully active despite its lack of 
disulfide bridges.  The peptide – an analogue of the murine β-defensin Defb14 – 
contains a single cysteine residue that is crucial to its chemotactic activity.  This 
chapter studies the importance of this amino acid with regard to the peptide’s overall 
structure. 
3.1 Introduction 
As described previously, the three-dimensional structure of -defensins is defined by 
a characteristic pattern of intramolecular disulfide bonds between six highly-
conserved cysteine residues.1-3  In a key study in 2003, Lu and co-workers showed 
that the ability of human -defensin 3 to chemoattract immune cells is highly 
dependent on how the cysteines are connected.4  Six topological analogues of HBD3, 
differing only in the connectivities of the disulfide bonds, were synthesised and their 
ability to attract monocytes and cells expressing CCR6 was assayed.  The analogues 
displayed a range of chemotactic activities, spanning three to four orders of 
magnitude.  A further variant, in which all cysteines were replaced with -
aminobutyric acid, was found to be inactive. 
Subsequently, Taylor et al. described synthetic analogues of HBD3 and its mouse 
orthologue Defb14 (Figure 3.1) that each have only one cysteine but possess 
chemotactic activities equivalent to their parent peptide in vitro.5  The location of this 
cysteine residue is important: the peptide is active with cysteine in the fifth position 
(CysV) but inactive with cysteine in the first position (CysI).  In agreement with the 
work of Lu and colleagues, Taylor et al. also observed that cysteine-free derivatives 
of HBD3 and Defb14, in which each cysteine was replaced by alanine, do not 
chemoattract.  In all cases, the absence of disulfide bonds did not impede the 





Figure 3.1 Sequences of HBD3, Defb14 and its analogues Defb14-1CysV and Defb14-
0Cys 
Cysteine to alanine mutations highlighted in bold.  Disulfide bonds of HBD3 and Defb14 are 
omitted for clarity. 
The discovery of active -defensin analogues that lack intramolecular disulfide 
bonds has important consequences.  One of the greatest obstacles to the development 
of -defensins as drugs is the expense of manufacturing peptides of sufficient purity.6  
It is therefore important to identify the minimum structural requirements for 
biological activity.  The synthesis of native -defensins is particularly challenging 
because of the intricacy required to obtain the ‘correct’ fold: a mixture of isomers is 
often obtained during oxidation of the cysteines.4, 7  Removing the need for 
intramolecular disulfide bond formation would eliminate this step and help decrease 
the cost of manufacture. 
Taylor et al. showed that replacing CysV with alanine results in a loss of chemotactic 
activity.  Whilst this demonstrates that CysV is essential to the chemoattractant 
properties of Defb14, it raises the question: does the side-chain of this cysteine 
interact directly with the chemokine receptor, or is this residue important to the 
conformation of the rest of the molecule? 
In this chapter, the role of CysV within Defb14 is investigated.  The single-cysteine 
containing peptide Defb14-1CysV was chemically modified to obtain three 
derivatives as shown in Figure 3.2.  Thus, the reactivity of the thiol group in cysteine 
was exploited to obtain a series of single-point mutants without the need for further 
peptide synthesis.  These derivatives were chosen so that this group of peptides 
contained a variety of different functional groups in the place of CysV.  The 
chemotactic activity of each peptide was then assayed and the structures of these 
derivatives were probed by ion mobility-mass spectrometry to establish possible 
links between structure and activity. 








Figure 3.2 Structure of the single-cysteine derivatives, Defb14-1XV 
 
X = Cys represents the unmodified single-cysteine peptide. Cy-1 denotes the 
carboxymethylated derivative, Cy-2 the carboxamidomethylated derivative and Cy-3 the 
ethylamine derivative. 
3.2 Experimental 
3.2.1 Peptide synthesis 
All peptides were chemically synthesised by standard solid-phase methodology as 
described previously.5  Defb14-1CysV was obtained from Albachem Ltd. 
(Gladsmuir, UK) and subsequently derivatised by Emily Seo and David Clarke.  
Further detail is available elsewhere8 but, in brief, Defb14-1CysV was reduced with 
tris(2-carboxyethyl)phosphine and then reacted with either iodoacetate, 
iodoacetamide or bromoethylamine hydrobromide.  This yielded the 
carboxymethylated derivative, Defb14-1(Cy-1)V, the carboxyamidomethylated 
derivative, Defb14-1(Cy-2)V, and the ethylamine derivative, Defb14-1(Cy-3)V, 
respectively (Figure 3.2).  Defb14-0Cys was synthesised by Derek Macmillan. 
3.2.2 Chemotaxis assays 
The chemotactic activity of Defb14-1CysV and its derivatives was assessed by Karen 
Taylor as reported previously.5  In this assay, the migration of human embryonic 
kidney (HEK293) cells expressing CCR6 in response to peptides at different 
concentrations was measured. 
3.2.3 Mass spectrometry 
Samples were prepared at a peptide concentration of 50 M in either buffered (10 
mM ammonium acetate) or denaturing (49.5% water, 49.5% methanol, 1.0% formic 






(Waters, Manchester, UK), with ions produced by positive nano-electrospray 
ionization.   Tuning conditions were identical for each sample. 
3.2.4 Ion mobility-mass spectrometry 
Samples were prepared and ionised by nESI as described above (section 3.2.3).  Ion 
mobility measurements were made using the MoQToF instrument as detailed 
previously.9  For each of the experiments in this chapter, the drift cell was filled with 
helium at a pressure of 3.0-3.5 Torr and a temperature of 37 ± 5 °C.  The electric 
potential difference across the cell was varied from 60 to 15 V, with measurements 
taken at eight different voltages. 
3.2.5 Theoretical collision cross-section of Defb14 
At present there is no NMR or X-ray crystal structure available in the protein 
databank for Defb14.  Given the well-conserved tertiary structure of -defensins and 
the high sequence homology of the peptides (Figure 3.1), HBD3 is considered to be a 
good template for Defb14.10  Homology modelling of Defb14 was performed on the 
SWISS-MODEL homology modelling server,11 using the NMR structure of HBD3 as 
a template.12  The rotationally-averaged collision cross-section of this structure was 
then calculated according to both the exact hard-spheres scattering model (EHSS) 
and the trajectory method, using the program Mobcal.13, 14 
In addition, to represent a theoretical structure of a fully-extended peptide, a model 
of Defb14-1CysV was built as a linear chain of amino acids in Leap.15  A limited 
energy minimisation of this structure was performed without further geometry 
optimisation and the collision cross-section of this structure calculated using Mobcal. 
3.3 Results and discussion 
3.3.1 Chemotaxis assays 
The unmodified peptide, the carboxymethylated (Defb14-1(Cy-1)V) and the 
carboxamidomethylated (Defb14-1(Cy-2)V) derivatives were found to induce 
migration of significantly (p < 0.05) more cells than control medium alone.8  In 





1(Cy-3)V) rendered the peptide unable to induce cell migration, as observed for the 
cysteine-free peptide Defb14-0Cys.8 
Clearly small chemical changes at a single residue of Defb14-1CysV – a forty-five 
amino acid peptide – greatly influence its ability to act as a chemoattractant.  Given 
that Defb14-1(Cy-1)V and Defb14-1(Cy-2)V have similar activities to Defb14 and 
Defb14-1CysV despite the different functional groups of the side-chain at position V, 
it would appear unlikely that CysV interacts directly with CCR6. 
3.3.2 Mass spectrometry 
The mass spectrum of each peptide displays several charge states corresponding to 
protonated species [M+zH]z+ generated by nano-electrospray ionisation.  In both 
ammonium acetate and acidified water/methanol, charge states z = 3-9 are observed 
for each derivative of Defb14-1CysV (Figures 3.3 and 3.4).  In comparison, 
[M+7H]7+ was the most highly-charged species observed by McCullough et al. for 
the wild-type Defb14 on the same instrument.9  This difference in charge state 
distribution can be attributed to the presence of three disulfide bridges in the wild-
type Defb14, which constrict the conformation of the peptide in solution and thus 
limit the availability of sites available for protonation in the nESI process. 
Under buffered conditions the charge state distribution of each derivative is centred 
around [M+5H]5+, whereas under denaturing conditions there is an increase in the 
population of higher charge states, with the most intense peak being [M+6H]6+.  In 
solution, the peptide structure is expected to change to maximise favourable solute-
solvent interactions, which are dependent on the pH and hydrophobicity of the 
solution.16  Such changes in the solution-phase conformation of a peptide are often 
reflected in a change in the charge state distribution in the mass spectrum.17  In this 
case, it appears that the presence of acid and organic solvent induces slightly more 
open conformations of the peptides in solution prior to ionisation. 
Despite the different functional groups introduced at CysV, the mass spectra of the 
derivatives are remarkably similar to each other.  Thus by mass spectrometry alone it 






Figure 3.3 Mass spectra of the derivatives Defb14-1XV in 10 mM ammonium acetate 
z= 9+  8+   7+       6+            5+                  4+                                  3+












Peptides: (a) Defb14-1(Cy-1)V; (b) Defb14-1(Cy-2)V; (c) Defb14-1(Cy-3)V. Charge states 
[M+3H]3+ to [M+9H]9+ are highlighted in grey.  Peaks marked with an asterisk (*) correspond 





Figure 3.4 Mass spectra of the derivatives Defb14-1XV in 49.5% water, 49.5% 
methanol, 1% formic acid 
z= 9+  8+   7+       6+            5+                  4+                                  3+













Peptides: (a) Defb14-1(Cy-1)V; (b) Defb14-1(Cy-2)V; (c) Defb14-1(Cy-3)V. Charge states 
[M+3H]3+ to [M+9H]9+ are highlighted in grey.  Peaks marked with an asterisk (*) correspond 
to peptide fragments formed in-source. 
3.3.3 Ion mobility-mass spectrometry 
Collision cross-sections under buffered conditions 
A single, relatively narrow arrival time distribution is observed for all species studied 
by IM-MS under buffered conditions (as illustrated in Figure 3.5 for the [M+9H]9+ 
ions).  This implies that the gas-phase conformations adopted by each peptide ion are 
closely-related in size.  In addition, the widths of the arrival time distributions are 
comparable for each peptide at a given charge state, indicating that each of the 





















Drift times for the [M+9H]9+ charge state of each peptide at a drift voltage of 20 V: (a) 
Defb14-1(Cy-1)V; (b) Defb14-1(Cy-2)V; (c) Defb14-1(Cy-3)V. Drift times are scaled to 3.5 Torr 
and 37 oC to account for fluctuations in pressure and temperature between experiments 
The mean collision cross-section of each ion increases with increasing charge (Table 
3.1), which can be attributed to expansion of the peptide structure to minimise 
Coulomb repulsion as an increasing number of protons are accepted.18, 19   When 
ionised from 10 mM ammonium acetate, similar collision cross-sections are 
measured for each of the derivatives at a given charge state. 
An exception is that the [M+3]3+ ion of Defb14-1(Cy-2)V is larger than the same 
charge state of Defb14-1(Cy-1)V and Defb14-1(Cy-3)V.  In this case, it is possible 
that the ‘fixed’ charges on the side-chains of Cy-1 and Cy-3 are involved in 
electrostatic interactions that constrict the structure of these ions at low charge states; 





















































at higher charge states, these proposed interactions may be less important as the 
peptide unfolds with increasing charge. In the main, however, it appears that the 
peptide derivatives in this study adopt similar gas-phase conformations to each other 
upon ionisation from aqueous buffer. 
Table 3.1 Mean collision cross-sections (Å2) under buffered conditions 
 Defb14-1(Cy-1)V Defb14-1(Cy-2)V Defb14-1(Cy-3)V 
[M+3H]3+ 586 ± 3 666 ± 28 586 ± 7 
[M+4H]4+ 761 ± 5 768 ± 10 777 ± 10 
[M+5H]5+ 987 ± 8 973 ± 17 969 ± 9 
[M+6H]6+ 1033 ± 4 1040 ± 11 1056 ± 12 
[M+7H]7+ 1060 ± 18 1087 ± 18 1071 ± 8 
[M+8H]8+ 1110 ± 17 1126 ± 23 1136 ± 11 
[M+9H]9+ 1176 ± 19 1218 ± 18 1200 ± 12 
Errors are quoted as the standard error of the mean. 
To survey a wider range of possible conformations, and to examine the ease with 
which the peptides unfold, the peptides were also ionised from an acidified solution 
of water/methanol. 
Collision cross-sections under denaturing conditions 
As with the buffered conditions, a single arrival time distribution is observed for the 
ions generated from an acidified solution of water/methanol (Figure 3.6).  However, 
the peaks are wider in the mobility spectra recorded under denaturing conditions: this 
shown in Figure 3.7 for the [M+9H]9+ ion of Defb14-1(Cy-1)V and is observed for all 





















Drift times for the [M+9H]9+ charge state of each peptide at a drift voltage of 20 V: (a) 
Defb14-1(Cy-1)V; (b) Defb14-1(Cy-2)V; (c) Defb14-1(Cy-3)V. Drift times are scaled to 3.5 Torr 
and 37 oC to account for fluctuations in pressure and temperature between experiments 
This observation implies that the peptides produced from acidified solution possess a 
greater range of peptide conformations in the gas-phase, though these different 
structures within a single charge state cannot be resolved on this IM-MS instrument.  
Separation of these various peptide conformations may be possible on higher-
resolution instruments, in which the drift time is extended by the use of longer drift 
tubes20 or larger, more polarisable buffer gases.21  Increasing the pressure of the 
buffer gas would also provide better resolution. 





















































Figure 3.7 Drift time distributions under buffered and denaturing conditions 
Drift times are for the [M+9H]9+ ion of Defb14-1(Cy-1)V at a drift voltage of 20 V and are 
scaled to 3.5 Torr and 37 oC to account for fluctuations in pressure and temperature between 
experiments. 
Again an increase in collision cross-section with increasing charge is observed for 
the peptides (Table 3.2).  When these cross-sections are compared with those 
obtained from aqueous buffer (Table 3.1), it is evident that there is a steeper increase 
in size between [M+5H]5+ and [M+9H]9+ for the species under denaturing conditions.  
Together with the increased peak width, this indicates the derivatives have greater 
conformational flexibility under these denaturing conditions. 
Although all peptide ions exhibit a greater range of sizes under denaturing 
conditions, the average cross-sections of some peptide ions are smaller under 
denaturing conditions than under buffered conditions, especially at lower charge 
states.  It is possible that this reflects the solution-phase change from unstructured 
peptide to helical peptide upon the addition of methanol.22 





















Table 3.2 Mean collision cross-sections (Å2) under denaturing conditions  
 Defb14-1(Cy-1)V Defb14-1(Cy-2)V Defb14-1(Cy-3)V 
[M+3H]3+ n.o. n.o. n.o. 
[M+4H]4+ 673 ± 13 676 ± 20 n.o. 
[M+5H]5+ 753 ± 13 758 ± 3 924 ± 32 
[M+6H]6+ 906 ± 22 909 ± 8 1021 ± 3 
[M+7H]7+ 1029 ± 15 1037 ± 3 1127 ± 12 
[M+8H]8+ 1089 ± 16 1123 ± 5 1235 ± 20 
[M+9H]9+ 1162 ± 7 1212 ± 4 1328 ± 31 
Errors are quoted as the standard error of the mean.  Species marked n.o. were not 
observed in sufficient intensity to accurately determine collision cross-sections by IM-MS. 
It is clear that the different solution conditions have resulted in different geometries 
post-ionisation.  For example, the [M+4H]4+ to [M+6H]6+ ions of Defb14-1(Cy-1)V 
and Defb14-1(Cy-2)V are more compact under denaturing conditions than the 
equivalent ions produced from ammonium acetate.  Meanwhile Defb14-1(Cy-3)V is 
more extended at z = 7-9 under denaturing conditions. 
The ability to distinguish between protein ions obtained from different solutions has 
been reported previously: for example Jarrold and co-workers measured different 
cross-sections for ions of cytochrome c produced from buffered, acidified and 
methanol-denatured solutions.23  Here, a similar approach shows how a single 
chemical change in the sequence of a given polypeptide can significantly alter the 
ease by which it can unfold, and by inference its structural stability, as seen in the 
relative changes of collision cross-section versus charge state. 
Comparison of chemotactic and non-chemotactic peptide conformations 
For comparison, a panel of peptides has been constructed that, in addition to the three 
derivatives of Defb14-1CysV investigated as part of this thesis, consists of Defb14, 
Defb14-1CysV and Defb14-0Cys, whose cross-sections have been reported 
previously (reference 9 and Appendix 1). 
Under denaturing conditions, the carboxymethylated and carboxamidomethylated 





1CysV as [M+7H]7+ and [M+8H]8+ ions and similar to wild-type Defb14 for the 
charges states z = 4-7.  The ethylamine derivative and Defb14-0Cys have 
significantly larger collision cross-sections than Defb14-1CysV as [M+7H]7+ and 
[M+8H]8+ ions and greater than Defb14-1(Cy-1)V, Defb14-1(Cy-2)V and wild-type 
Defb14 across all of the observed charge states. 
From these observations it appears that the small changes to the functionality at CysV 
have altered the conformational preferences of the peptides.  It is not surprising that 
the modification a single amino acid can induce changes in the fold of a protein or 
peptide: it is well-documented that mutations can shift the equilibrium between 
native and unfolded states.24  Indeed, in some cases a small number of changes can 
give rise to completely distinct tertiary structures.25  A dramatic example of this is 
the synthetic system designed by Alexander et al., in which a single amino acid 
substitution changes the protein fold completely from -helix to β-sheet (and vice 
versa).26 
The peptides with chemotactic activity are significantly more compact at higher 
charge states than those that do not chemoattract, suggesting that the active peptides 
experience less Coulomb-driven unfolding in the gas-phase.  This is illustrated by 
considering the percentage change in the observed collision cross-section for the 
modified peptides versus unmodified Defb14-1CysV (Figure 3.8). 
The change in collision cross-section due to the size of the substituent does not 
appear to be a factor here, since the smallest substituent (X = Ala) gives the second 
largest collision cross section for z = 6, 7 and 8.  The Cy-3 and Cy-1 side-chains are 
of comparable size but the collision cross section for the z = 8 ion of Defb14-1(Cy-
3)V is 12% larger than that observed for the Defb14-1(Cy-1)V.  This may be due to 
electrostatic effects: if the amino group of Cy-3 is protonated, given its proximity to 
the basic residues in the C-terminus of the peptide, it is likely that it will induce local 
unfolding due to electrostatic repulsion. The Cy-1 acidic group if deprotonated will 
interact favourably with the protonated basic groups thus tightening the conformation 





Figure 3.8 Comparison of collision cross-sections of Defb14 and Defb14-1XV 











In considering the protonation state of the carboxymethyl and ethylamine derivatives, 
one can approximate the functional groups of Cy-1 and Cy-3 to the side-chains of 
aspartic acid (pKa ~ 3.9) and lysine (pKa ~ 10.5) respectively.
27  This implies that Cy-
1 is mostly charge-neutral in 1% formic acid (pH ~ 2.5), whilst Cy-3 is highly likely 
to be protonated.  If these protonation states were preserved post-ionisation, it would 
explain the greater collision cross-sections observed for Cy-3 compared to Cy-1 and 
Cy-2 under denaturing conditions.  However, aspartic acid (and by inference Cy-1) is 
readily deprotonated in the gas-phase.28  In addition, there was no evidence of this 
solvent memory effect upon ionisation from ammonium acetate (pH 6.8), from which 
the collision cross-sections were indistinguishable despite the likely differences in 
protonation state. 
The difference between the conformations of the unmodified peptide and the non-
chemotactic derivatives is most pronounced at elevated charge states.  Other 
researchers have also reported greater resolution of related structures at higher charge 
states by IM-MS: for example Hill and colleagues could resolve the sequence-
reversed oligopeptides SNGRG and GRGNS as [M+2H]2+ ions but not [M+H]+ 
ions.29  This may reflect a divergence of three-dimensional structure as the peptides 



























In general, the active derivatives have similar cross-sections to those of the wild-type 
Defb14, although Defb14-1CysV has a larger cross-section than the other active 
peptides at low charge states (z = 5-6).  The reason for this is unclear but suggests 
that the unmodified cysteine peptide has a looser configuration than the other 
peptides with a smaller net number of charges.  
Interestingly, although the non-chemotactic peptides are generally larger than the 
chemotactic peptides at increased charge states, the width of the arrival time 
distributions is approximately the same (Figure 3.6).  This indicates that, although 
the sizes of the peptides vary, each exhibits a similar number of different 
conformations. 
The ability to discriminate between chemotactic and non-chemotactic peptides is 
dependent on the solution conditions prior to ionisation.  Under buffered conditions 
(Table 3.1 and Appendix 2), the peptides generally adopt similar geometries and it is 
not possible make any distinction between the peptides of different activities.  From 
a solution of acidified water/methanol, the peptides have a greater degree of 
conformational flexibility and can adopt different three-dimensional structures, as 
observed both by the widening of the arrival time distributions (Figure 3.7) and the 
relative change in the collision cross-sections for the substituted peptides.  It is 
possible that the greater structural freedom afforded by these solutions conditions 
allows the peptides to explore conformations that also exist upon interaction with 
CCR6.  Although this choice of solvent is clearly not representative of the 
environment of the chemokine receptor in vivo, it does allow an in vacuo method to 
distinguish between ions from chemotactic and non-chemotactic peptides for this set 
of -defensin derivatives. 
3.3.4 Theoretical collision cross-section of Defb14 
For comparison with the ion mobility data, a three-dimensional model of Defb14 was 
obtained by homology modelling (Figure 3.9) and was used as an estimate of the 
solution-phase structure of Defb14.  The collision cross-section of this structure was 
calculated and compared with the cross-section of a theoretical, fully extended 





Figure 3.9 Model structure of Defb14 based on homology to HBD3 
 
In the above model, the amide backbone is shown in cyan.  All other atoms are shown in the 
CPK style. 
Table 3.3 Collision cross-sections (Å2) calculated for model structures 
 EHSS TM 
Defb14 (homology) 900 872 
Defb14-1CysV (extended) 1624 a 
a The TM calculation for the extended structure failed, presumably because of its unrealistic 
geometry. 
Comparison of the collision cross-sections calculated for the theoretical models and 
those determined experimentally for the derivatives (Tables 3.1 and 3.2) reveals a 
couple of interesting points.  First, the lowest charge states of the derivative ions are 
more compact than the homology model.  This effect is commonly observed in the 
study of proteins in the gas-phase and is known as a ‘hydrophobic collapse’.30  In 
solution, the side-chains of polar amino acids will be orientated outwards to interact 





environment of the gas-phase, these residues will tend to turn inwards to maximise 
favourable interactions, resulting in a more compact conformation. 
For higher charge states, Coulomb repulsion results in expansion of the peptide 
structure and mitigates this effect.  Therefore, as the derivatives unfold in the gas-
phase their collision cross-sections become larger than those obtained for the 
homology model of Defb14 in solution.  However the peptides never become as 
large as the fully extended model of Defb14-1CysV.  Thus it can be concluded that 
the derivatives do not unfold completely and retain some degree of structure, even 
under denaturing conditions and at the highest observable charge states. 
3.4 Conclusions 
Taylor et al. illustrated the importance of CysV to the chemotactic activity of HBD3 
and Defb14.5  In this thesis it has been shown that modification of CysV alters the 
unfolding behaviour of linear Defb14 analogues (as evidenced by the differences in 
collision cross-sections under denaturing conditions).  Further investigation is 
required to fully understand how these subtle chemical changes alter the ability of the 
peptide to interact favourably with CCR6. 
Ion mobility-mass spectrometry has been used to probe the tertiary structures of 
single-cysteine Defb14 derivatives.  The conformations of these peptides in the gas-
phase are dependent on the solvent environment prior to ionisation.  Under 
denaturing conditions, the peptide ions exhibit greater conformational freedom and 
the chemotactic peptides can be distinguished from non-chemotactic derivatives on 
the basis of their collision cross-section.  Ion mobility-mass spectrometry has been 
used to great effect in several previous studies to probe the unfolding of proteins18 
and, taking a similar approach, here it has been shown how small chemical changes 
to the structure of a peptide can significantly affect its gas-phase unfolding 
behaviour. 
Traditionally, the energy of protein folding is determined by differential scanning 
calorimetry, in which the heat absorption upon thermal denaturation of the protein is 
measured.31, 32  Additionally, protein stability can be assessed by quantifying the 





these methods could be used in future work to establish if the differences in the gas-
phase unfolding of the Defb14-1CysV derivatives are observed also in solution. 
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4 N-terminal modifications of Defb14-1CysV 
 
In the previous chapter, the role of a residue near the C-terminus of Defb14-1CysV 
was investigated.  In this chapter, the importance of the other end of the molecule, 
the N-terminus, is considered in terms of the chemotactic and antimicrobial activity 
of the peptide. 
4.1 Introduction 
In the preceding chapter it was concluded that the single cysteine residue in Defb14-
1CysV is not likely to interact directly with the chemokine receptor CCR6.  In 
another study, Rohrl et al. produced a fusion protein that comprised an 
immunoglobulin attached to the C-terminus of Defb14, which chemoattracted cells 
expressing CCR6.1  This suggests that the C-terminal region of Defb14 can tolerate 
some degree of structural adjustment without losing its chemotactic activity.  Taken 
together, these results imply that it is likely to be the N-terminal region of Defb14 
that interacts with CCR6. 
This hypothesis is supported by a study of human β-defensin 1, conducted by 
Lubkowski and colleagues, in which a large number of HBD1 analogues were 
produced with single-point mutations at various positions of the peptide sequence.2  
With regard to chemotactic activity, the most deleterious substitutions were found to 
occur in the N-terminal -helical section.  Analysis by X-ray crystallography 
revealed that the mutations did not significantly alter the peptide’s tertiary structure, 
implying that the change in biological function results from changes in the chemical 
functionalities of the amino acid side-chains. 
In addition to its potential significance for chemotaxis, the N-terminal region of 
Defb14 is also important to the antimicrobial activity of the peptide.  In 2008, Taylor 
et al. synthesised two analogues of Defb14-1CysV: one corresponding to the N-
terminal half of the peptide, the other to the C-terminal side, each being of similar 
length and net charge.3  Whilst the C-terminal fragment was found to be inactive 





full-length peptide in vitro.  This difference in activity was attributed to the greater 
number of hydrophobic residues that are present in the N-terminal half.  In contrast, 
Lubkowski and co-workers found that the activity of HBD1 against E. coli could be 
ascribed to four basic residues at C-terminus. 
In this chapter, two series of Defb14 analogues are described: one comprising 
successive N-terminal truncations of Defb14-1CysV (Figure 4.1); and one containing 
single-point mutations of Defb14-1CysV (Figure 4.2).  The chemotactic and 
antimicrobial activity of these derivatives was assayed.  The biological activity of the 
peptides is discussed with reference to their structures, which were examined by 
circular dichroism spectroscopy, high performance liquid chromatography and ion 
mobility-mass spectrometry.  
Figure 4.1 N-terminal truncated analogues of Defb14-1CysV 
The amino acids deleted in the truncated peptides are shown in brackets after the  sign.  
Each truncated peptide was synthesised with an acetyl group at the N-terminus rather than 
the free amino group as in Defb14-1CysV. 
Figure 4.2 Single-point mutated analogues of Defb14-1CysV 
The amino acid substitutions at position 2 are shown in bold. 
Defb14-1CysV: FLPKTLRKFFARIRGGRAAVLNALGKEEQIGRASNSGRKCARKKK 
(1-2):   PKTLRKFFARIRGGRAAVLNALGKEEQIGRASNSGRKCARKKK 
(1-5):      LRKFFARIRGGRAAVLNALGKEEQIGRASNSGRKCARKKK 
(1-8):         FFARIRGGRAAVLNALGKEEQIGRASNSGRKCARKKK 
(1-11):            RIRGGRAAVLNALGKEEQIGRASNSGRKCARKKK 
(1-14):               GGRAAVLNALGKEEQIGRASNSGRKCARKKK 










4.2.1 Peptide synthesis 
All peptides (Figures 4.1 and 4.2) were chemically synthesised by standard solid-
phase methodology as described.4, 5  Each truncated peptide was synthesised with an 
acetyl group at the N-terminus (thus giving an amide bond rather than the free amino 
group) to best represent the conformation of the terminal amino acid as it exists in 
the full-length peptide. 
4.2.2 Chemotaxis assays 
The migration of human embryonic kidney (HEK293) cells expressing CCR6 in 
response to peptides at different concentrations was measured using a 
microchemotaxis chamber.  These assays were performed by Kirsty Tyrrell as 
described.4 
4.2.3 Bactericidal assays 
The minimum bactericidal concentration (MBC) of each peptide was determined for 
Pseudomonas aeruginosa and Staphylococcus aureus.4, 5  These assays were 
performed by Natalie Reynolds.  The MBC is defined as the concentration of peptide 
required for >99.99% killing of the initial inoculum.  Reduction of the peptides, 
where performed, was performed by the addition of 10 mM dithiothreitol (DTT) to 
the peptide solution.  DTT was used to prevent dimerisation of the peptides via 
cysteine oxidation and the oxidation state of each peptide was confirmed by mass 
spectrometry. 
4.2.4 High performance liquid chromatography 
Reversed-phase high performance liquid chromatography (HPLC) was employed to 
evaluate the relative molecular hydrophobicity of the N-terminal truncation peptides.  
Samples were prepared both in water and in 10 mM DTT.  Each sample contained 50 
M peptide plus 50 M melittin (Sigma) as an internal standard. 
Using an Ultimate 3000 LC system (Dionex), 30 l of each sample was injected onto 
a Waters Symmetry C18 column (3.9 x 150 mm).  Initial buffer conditions were as 





(4% water, 95% acetonitrile, 1% formic acid); flow rate 1 ml min-1.  These 
conditions were held for 3 minutes before commencing a linear gradient of 0 – 40% 
eluent B over 40 minutes.  Detection by mass spectrometry was performed by 
splitting the flow 1/50 prior to introduction to the ESI source of a VG Platform II 
mass spectrometer. 
The hydrophobicity of each peptide is proportional to the time it is retained on the 
column.  This is quoted relative to the peptide melittin, as described below: 









r   
where r is the relative retention time and tR' is the adjusted retention time (i.e. the 
retention time minus the column dead time). 
4.2.5 Circular dichroism spectroscopy 
CD spectroscopy was used to probe the secondary structures of peptides in: (i) 10 
mM ammonium acetate, pH 6.8, and (ii) 50% water, 50% 2,2,2-trifluoroethanol 
(TFE).  CD spectra were recorded over the wavelength range 190 – 260 nm at 20 °C 
using a Jasco J-810 spectropolarimeter.  A total of five scans were acquired for each 
sample and averaged to give a final sample spectrum.  Buffer in the absence of 
peptide was used as a reference.  Peptide concentration was determined by assaying 
with bicinchoninic acid (Pierce)6 and the mean residue ellipticity was calculated at 
each wavelength. 
The CDSSTR algorithm7 on the DICROWEB server8 was used to help the assign 
secondary structure.  As this algorithm is only applicable to peptides in aqueous 
solution, the percentage helicity in 50% TFE was estimated from the ellipticity at 







































4.2.6 Ion mobility-mass spectrometry 
Both the truncated and point mutation series of peptides were analysed by IM-MS on 
the MoQToF as described previously.11  Peptides were prepared at a concentration of 
50 M.  The truncated peptides were dissolved in 10 mM ammonium acetate plus 10 
mM dithiothreitol; the mutatation peptides were ionised from 49.5% water, 49.5% 
methanol, 1.0% formic acid.  For these experiments, the temperature and pressure of 
helium in the drift cell was ~ 28 °C and ~ 3.4 Torr respectively.  Measurements were 
made at eight different drift voltages from 60 to 15 V. 
4.3 Results and discussion 
4.3.1 Chemotaxis activity 
N-terminal truncations 
The assays reveal that none of the truncated peptides are chemotactic; only the full-
length Defb14-1CysV peptide chemoattracts cells expressing CCR6.4  Loss of the 
first two amino acids (phenylalanine and leucine) renders the peptide inactive, thus 
one or both of these residues are crucial to the chemotactic activity of the peptide.  
Comparison of homologous peptides across several mammalian species reveals that 
the second amino acid is often either leucine or its isomer isoleucine.4  In contrast, 
the first residue is much less well conserved, suggesting that it is the second amino 
acid (leucine) that is more important. 
N-terminal modifications 
To test the hypothesis that the chemotactic activity of Defb14-1CysV is dependent on 
the nature of the second amino acid, a series of mutant peptides was synthesised in 





The L2G and L2K mutants were found to be inactive, whilst the chemotactic activity 
of the L2I peptide was reduced.4 
These data confirm that the second amino acid is vital to peptide’s ability to act as a 
chemoattractant.  The modest activity of the L2I peptide can be explained by the fact 
that leucine to isoleucine is a conservative substitution since both amino acids are 
hydrophobic and of similar size.  More drastic changes in the chemical functionality, 
such as to glycine or positively-charged lysine, are not tolerated. 
4.3.2 Bactericidal activity 
N-terminal truncations 
For this series of peptides, the general trend is that the MBC increases (i.e. activity 
decreases) as more amino acids are removed from the N-terminus.5  However, 
significant antimicrobial activity is retained even upon deletion of the first eleven 
residues.  Thereafter, the monomeric peptides become much less potent upon 
deletion of further amino acids.  
Interestingly, truncation of the dimeric peptides does not diminish the activity against 
P. aeruginosa as much as it affects the monomeric peptides.  As dimers, even the 
(1-14) and (1-17) peptides are potent antimicrobials.5  Similarly, other defensin-
related peptides possess greater antimicrobial activity as covalent dimers than as 
monomers or non-covalent dimers.12, 13  The greater activity of the dimers may stem 
from a number of factors, including better protection against bacterial proteases or 
differences in their hydrophobicity and charge. 
N-terminal modifications 
The antimicrobial activities of the Defb14-1CysV mutants did not differ significantly 
from the parent peptide and therefore the nature of the second amino acid is relevant 
only to the chemotactic properties of Defb14 and not to its antimicrobial activity.4 
4.3.3 Hydrophobicity and charge 
Hydrophobicity 
The relative hydrophobicity of the N-terminal truncation peptides was evaluated by 





for the analysis of the monomer and dimer respectively.  HPLC was not performed 
for the N-terminal modification peptides since no variation in antimicrobial activity 
was observed for the single point mutants. 
For every peptide analysed, the dimer was retained on the column longer than the 
monomer: an example of this is shown for the (1-17) peptide (Figure 4.3), with the 
relative retention times of all the peptides shown in Figure 4.4.  This indicates that in 
each case the dimer is more hydrophobic than the monomer.  
This is not intuitive from inspection of the primary structure of the peptides alone.  
Several scales that have been established to estimate the hydrophobicity of peptides 
based on their sequence.14-17  A hydrophobicity ‘score’ is obtained for every amino 
acid by measuring the partitioning of individual residues between hydrophobic and 
hydrophilic solvent phases.  The hydrophobicity of a peptide can then be 
approximated by simple addition of the scores for each amino acid that comprises the 
primary structure.  Figure 4.5 shows the hydrophobicities of the N-terminal 
truncation peptides estimated using the scale of Wimley and White.17  It can be seen 
that, contrary to what is observed experimentally, this scale predicts the dimers to be 
less hydrophobic than the monomers. 










Selected ion chromatograms for (1-17) (a) monomer and (b) dimer ions at m/z 606, 
corresponding to the [M+5H]5+ and [M+10H]10+ charge states respectively.  The 
hydrophobicity of each peptide is proportional to the time it is retained on the column. 
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Increasing hydrophobicity is denoted by an increased retention time.  All values are quoted 
relative to the retention time of the peptide melittin. 
Figure 4.5 Relative hydrophobicity scores of the N-terminal truncation peptides as 






























































Thus the dimer hydrophobicity is not well represented by treating the amino acids in 
an additive fashion.  This discrepancy arises because this theoretical approach does 
not consider the tertiary structures of the peptides.  It follows that these dimers are 
more hydrophobic because of their three-dimensional structure: presumably a 
number of charged residues are involved in electrostatic interactions between the 
monomer subunits and are therefore orientated inwards, whilst a greater proportion 
of hydrophobic residues reside at the outer surface of the peptide. 
Comparison of the relative retention times of the different peptides reveals little 
change in hydrophobicity from the full length Defb14-1CysV to (1-8).  Thereafter, 
deletion of the amino acids FFA causes an appreciable decrease in hydrophobicity, 
however this does not result in a significant decrease in activity towards P. 
aeruginosa.  Loss of the next three amino acids RIR, i.e. truncation (1-14), gives 
rise to an increase in hydrophobicity, yet this corresponds to the point at which 
bactericidal activity of the monomeric peptide is lost.  Thus, it would appear that the 
variation in antimicrobial activity within this series of peptides cannot be ascribed 
solely to differences in their hydrophobicity. 
Charge 
Each of the peptides in this study with activity towards P. aeruginosa has a net 
charge greater than +7 (Table 4.1).  It is possible that, whilst the (1-14) and (1-17) 
monomers are inactive, the corresponding dimers are potent on account of their 
increased charge.  However the peptide (1-23), which has the same charge as (1-
17) but which lacks the hydrophobic residues AAVLNA, is reported by Taylor et al. 
to be inactive as both a monomer and a dimer.3  Therefore it may be that a balance of 
both charge and hydrophobicity is necessary. 
In addition, particular amino acid sequences may be important.  A recent study that 
showed that arginine-to-lysine mutations (which do not alter the charge of the 
peptide) were deleterious to the activity of an -defensin.18  The authors postulate 
that the arginine side-chains offer stronger interactions with the bacterial membrane.  






Table 4.1 Net charge of N-terminal truncation peptides 
 Net charge 
Peptide Monomer Dimer 
Defb14-1CysV 12+ 24+ 
(1-2) 11+ 22+ 
(1-5) 10+ 20+ 
(1-8) 8+ 16+ 
(1-11) 8+ 16+ 
(1-14) 6+ 12+ 
(1-17) 5+ 10+ 
(1-23)* 5+ 10+ 
The net charge is based on the protonation state of each amino acid side-chain and the 
termini at neutral pH.  The charges of peptides active towards P. aeruginosa are highlighted 
in bold.  *Data for peptide (1-23) is taken from reference (3) and is included for comparison. 
4.3.4 Circular dichroism spectroscopy 
N-terminal truncations 
A helical wheel projection of Defb14-1CysV (Figure 4.6a) predicts that the N-
terminal region of the full-length peptide has the potential to form an -helix, with 
charged residues concentrated on one face of the helix and hydrophobic residues on 
the other.  The distinction between hydrophilic and hydrophobic faces is less clear in 
helical wheel projections of the shorter peptides, for example truncation (1-14) 
(Figure 4.6b).  This suggests a lesser propensity to form an -helix, which may 
contribute to the diminished activity of the truncated peptides.  To verify this 






Figure 4.6 Helical wheel projections for Defb14-1CysV and (1-14) 
 
Schematic representation of Defb14-1CysV: (a) residues 1-18 and (b) residues 15-32, which 
correspond to the N-terminal regions of the full-length peptide and (1-14) respectively. 
Residues are plotted so that the angle of rotation between consecutive amino acids is 100°, 
giving a final representation that looks down the axis of helical rotation.  Charged residues 
are denoted by white circles; increasing hydrophobicity is denoted by increasing shading. 
The CD spectrum of each of the N-terminal truncations in aqueous solution exhibits 
a minimum at 201 nm (Figure 4.7) that is typical of a peptide whose secondary 
structure is a mixture of -sheet or -turn and random coil.  This is in good 
qualitative agreement with published CD spectra of other -defensins.19, 20 


























































































The addition of trifluoroethanol to an aqueous peptide solution can induce helix 
formation and is commonly used to evaluate the propensity of a given peptide to 
form an -helix.21  The minima observed at 208 and 222 nm in the spectra of each 
peptide in 50% TFE are characteristic of -helical structure (Figure 4.8).  The 
intensity of these minima decreases with decreasing chain length, corresponding to a 
reduction in the percentage helical content of the peptide as an increasing number of 
amino acids are deleted from the N-terminus (Figure 4.9).  This reflects a decreasing 
propensity to form an -helix, as suggested by the helical wheel projections. 
This may be pertinent to the varying antimicrobial activities of these peptides since 
the formation of helical oligomers is implicated in the pore model of antimicrobial 
action.22  It is notable, therefore, that the shortest peptides with the least helix-
forming potential also have the lowest potencies.  However, the modes of action of 
these peptides are not known and the killing mechanism of the truncated peptides 
may differ from that of the full-length peptide. 
































































To evaluate if the variation in chemotactic activity upon substitution of leucine-2 is 
the result of a change in secondary structure, CD spectroscopy was performed.  As 
observed with the other series of peptides, the CD spectrum of each peptide in 
aqueous solution (Figure 4.10) shows an absorption minimum at 201 nm that is 
consistent with a mix of unstructured peptide and -sheet/turn.  In buffer, Defb14-
1CysV exhibits a slightly more intense absorption minimum than that of the other 
peptides but was found to contain the same proportions of secondary structure as all 
of the other peptides according to analysis by the CDSSTR algorithm (Appendix 5).7  
If interaction with the chemokine receptor CCR6 occurs at the N-terminal region of 
Defb14, this corresponds to an -helical region of the peptide.  Upon the addition of 
TFE (Figure 4.11), all of these peptides form an -helix, as evident by the minima at 
208 and 222 nm, which strongly suggests that all of these peptides can readily form 
-helices under increased hydrophobic conditions, as might exist in the proximity of 

















































































































































The CD spectrum of Defb14-1 CysV in 50% TFE is indistinguishable from those of 
the substitution mutants (Figure 4.11).  This demonstrates that substitution of the 
leucine at position 2 has not diminished the helix-forming potential of the peptide 
and so the reduced chemotactic activity of the mutants is not due to impairment of 
the N-terminal helix.  In the absence of any evidence of structural change, it suggests 
that leucine-2 in Defb14 interacts directly with the chemokine receptor CCR6. 
4.3.5 Ion mobility-mass spectrometry 
N-terminal truncations 
As an increasing number of residues are deleted from the peptide, there is a shift 
towards narrower charge state distributions and a decrease in the highest charge state 
observed (Figure 4.12). 















Mass spectra of monomeric truncated peptides: (a) (1-8); (b) (1-14). 



















For example, charge states [M+3H]3+ to [M+8H]8+ are observed in the mass 
spectrum of the (1-8) peptide, compared to [M+2H]2+ to [M+6H]6+ for (1-14).  
This is due to the fact that as more amino acids are removed, fewer sites are available 
for protonation. 
Two general trends are apparent in the series of collision cross-sections measured for 
the N-terminal truncation peptides (Table 4.2).  First, the collision cross-section of 
each peptide increases with increasing charge state as a result of stronger Coulomb 
repulsion.  Second, as might be expected, the overall size of a peptide ion at a given 
charge state generally decreases with progressive N-terminal truncations. 
Table 4.2 Collision cross-sections (Å2) of N-terminal truncation peptides 
 (1-2) (1-5) (1-8) 
[M+2H]2+ n.o. - n.o. 
[M+3H]3+ 580 ± 22 - 638 ± 4 
[M+4H]4+ 688 ± 1 - 746 ± 7 
[M+5H]5+ 844 ± 18 - 883 ± 7 
[M+6H]6+ 925 ± 9 - 914 ± 17 
[M+7H]7+ 1008 ± 6 - 967 ± 24 
[M+8H]8+ 1106 ± 5 - 1021 ± 29 
[M+9H]9+ 1182 ± 9 - n.o. 
 
 (1-11) (1-14) (1-17) 
[M+2H]2+ 439 ± 14 397 ± 10 405 ± 16 
[M+3H]3+ 613 ± 3 515 ± 1 567 ± 9 
[M+4H]4+ 749 ± 4 628 ± 3 637 ± 12 
[M+5H]5+ 812 ± 13 689 ± 3 663 ± 12 
[M+6H]6+ 835 ± 21 780 ± 6 670 ± 3 
[M+7H]7+ 881 ± 21 n.o. n.o. 
[M+8H]8+ n.o. n.o. n.o. 
[M+9H]9+ n.o. n.o. n.o. 





An exception to this is the truncated peptide (1-2), which is actually smaller than 
the shorter peptide (1-8) at charge states [M+3H]3+ to [M+5H]5+.  As discussed 
above in section 4.3.4, the N-terminal region of Defb14-1CysV has the potential to 
form an -helix.   It is possible that the N-terminal amino acids of truncation (1-2) 
are part of an -helix (or other region of localised structure) that is preserved in the 
gas-phase at low charge states, leading to a more compact conformation. 
N-terminal modifications 
Ion mobility-mass spectrometry was used to probe the conformation of the N-
terminal modification peptides to establish if the range in chemotactic activities 
observed for this series of peptides is a result of differences in tertiary structure.  In 
the previous chapter, chemotactic peptides could be distinguished from non-
chemotactic peptides by IM-MS under denaturing conditions.  Based on this 
observation, the same solution conditions were used in this experiment.  As 
acknowledged previously, the solvent is not representative of the environment in vivo 
but is chosen to allow a wider range of conformations to be surveyed in vacuo. 
The mass spectra of the N-terminal modification peptides under denaturing 
conditions are shown in Figure 4.12.  Each peptide is observed in charge states 
[M+3H]3+ to [M+8H]8+, with no difference in the charge distribution of each peptide.  
The collision cross-sections of these ions are listed in Table 4.3.  The collision cross-
sections measured for the unmodified peptide, Defb14-1CysV, are available in 
reference (11) and in Appendix 1.  
Once again the collision cross-section of each peptide increases with increasing 
charge state.  At most charge states, the mean collision cross-section of each of the 
N-terminal modification peptides is the same within experimental error.  Moreover, 
similar arrival time distributions are observed (Figure 4.13), demonstrating that each 
peptide exhibits the same range of conformations.  An exception to this is the 
[M+5H]5+ ion of the L2K peptide, which is larger than both the L2G and L2I 
analogues.  In general, however, the mutants all adopt similar conformations in 




















Mass spectra of (a) L2G; (b) L2I; (c) L2K modification peptides.  Charge states [M+3H]3+ to 
[M+8H]8+ are indicated for L2G; a similar distribution is observed for the other peptides.  
Peaks marked with an asterisk (*) correspond to an adduct of mass +116 Da. 
Table 4.3 Mean collision cross-sections (Å2) of N-terminal modification peptides 
Peptide L2G L2I L2K 
[M+3H]3+ n.o. n.o. n.o. 
[M+4H]4+ 772 ± 6 777 ± 22 797 ± 4 
[M+5H]5+ 937 ± 6 925 ± 37 997 ± 2 
[M+6H]6+ 1029 ± 4 1030 ± 2 1045 ± 27 
[M+7H]7+ 1070 ± 13 1089 ± 18 1098 ± 3 
[M+8H]8+ 1128 ± 26 1101 ± 36 1126 ± 33 
Errors are quoted as the standard error of the mean.  Species marked n.o. were not 
observed at sufficient intensity to obtain accurate collision cross-sections by IM-MS. 
 










































Drift times for the [M+8H]8+ charge state of each N-terminal modification peptide at a drift 
voltage of 20 V: (a) L2I; (b) L2G; (c) L2K. Drift times are scaled to 3.5 Torr and 300 K to 
account for fluctuations in pressure and temperature between experiments 
The collision cross-sections of the mutants are generally larger than those reported 
for the unmodified peptide Defb14-1CysV.11  This may reflect a partial 
destabilisation of the three-dimensional fold upon substitution of leucine.  However, 
no distinction can be made between the tertiary structures of the peptides L2G, L2I 
and L2K despite their varying chemotactic activities.  Only the side-chain of the 
second residue was modified: the absence of any other observable structural change 
supports the hypothesis that the second amino acid of Defb14 interacts directly with 























































In this chapter, the N-terminal region of Defb14 was investigated using two series of 
peptides based on the single-cysteine peptide Defb14-1CysV.  Single-point mutations 
revealed that the second amino acid – leucine – is important to the chemotactic 
activity of this molecule.  Analysis by CD spectroscopy and IM-MS indicated that 
these modifications did not induce significant changes in the three-dimensional 
structure of the peptide.  These data, coupled with the observation that a conservative 
leucine-to-isoleucine substitution retains some chemotactic activity, suggest that the 
second residue interacts directly with the receptor CCR6. 
A succession of N-terminal truncations showed that deletion of up to eleven of the 
initial amino acids did not severely impair antimicrobial potency.  This has important 
implications for the design of peptide therapeutics, where there is a drive to identify 
active, shorter analogues since they are cheaper to manufacture.  Loss of further 
amino acids did result in a decrease in antimicrobial activity.  Using reverse-phase 
HPLC, it was established that this was not due to a reduction in hydrophobicity and 
therefore likely to be a result of decreased net positive charge.  In addition, the 
inactive peptides were shown by CD spectroscopy to have a lesser ability to form an 
-helix under more hydrophobic conditions, as would exist in the proximity of a 
bacterial membrane.  Whilst the mechanism by which these peptides kill bacteria 
remains unclear, this finding may be relevant if the peptides act by forming pores in 
the bacterial membrane since helix formation is required by this mechanism. 
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5 Interaction of human -defensins 2 and 3 with 
glycosaminoglycans 
 
In this chapter the ability of human -defensins 2 and 3 to behave like chemokines, 
particularly in terms of their oligomerisation properties and their interactions with 
glycosaminoglycans, is examined. 
5.1 Introduction 
-defensins share several structural and functional similarities to another family of 
immunomodulatory proteins known as chemokines.1, 2  Chemokines contain four 
highly conserved cysteine residues (compared with six in -defensins) that stabilise a 
well-defined three-dimensional structure.  The tertiary structure of chemokines 
contains three anti-parallel -strands and a C-terminal -helix, which is somewhat 
reminiscent of the characteristic fold of -defensins (Figure 5.1).  Chemokines are 
classified according to the spacing of the first two cysteines: for example these 
residues are adjacent in CC chemokines, whereas in CXC chemokines they are 
separated by one amino acid. 
Figure 5.1 Tertiary structures of the chemokine CCL20 (ref 3) and human -defensin 
3 (ref 4) 
 
NMR structures of the chemokine CCL20 (left) and HBD3 (right).  Both peptides contain 





-defensins and chemokines have a notable function in common: the ability to 
induce the migration of immune cells.5, 6  Indeed, this is the primary role of 
chemokines; their name deriving from the fact that they are chemotactic cytokines.  
The process of chemotaxis begins by the chemokine binding to and activating a G 
protein-coupled receptor (GPCR).  Interestingly, several chemokines bind more than 
one receptor and most receptors interact with numerous chemokines.  However, 
whilst it appears that there is a large degree of redundancy in this system, in general 
receptors are only activated by chemokines belonging to the same structural sub-
family (CC, CXC, etc.).  The chemokine CCL20 induces chemotaxis via the receptor 
CCR6.7  This receptor is also activated by some -defensins, including HBD2 and 
HBD3.5, 8  Similar to the CC chemokines, -defensins possess two adjacent cysteine 
residues, although these are located near the C- rather than N-terminus. 
An important attribute of chemokines that relates to their chemotactic activity is their 
ability to bind glycosaminoglycans (GAGs).1, 9  In an influential study, Proudfoot et 
al. mutated the GAG binding sites of three chemokines and assessed their 
chemotactic activity.10  All were active in vitro but could not recruit cells in vivo.  
GAGs are polysaccharides located on the surface of mammalian cells.  By binding to 
GAGs on the surfaces of cells, chemokines can overcome vascular flow in vivo to 
form a concentration gradient that is necessary for directional cell migration.  In 
addition to helping chemokines adhere to cells, it is speculated that GAGs may play a 
more active role in cell signalling.  It is believed that chemokines could be directed 
to different locations on the basis of their varying affinity for different types of 
GAG.11 
Another feature of the chemokine-GAG interaction is its effect on oligomerisation.1, 
12  Several chemokines are known to form oligomers in solution: most exist as 
dimers, though tetramers (effectively ‘dimers of dimers’) have also been observed.  
By binding to GAGs, the population of chemokine dimers is increased, whilst 
oligomerisation is promoted also for those chemokines that are observed only as 
monomers alone in solution.  McCornack et al. studied this quantitatively and found 
that GAG binding lowered the dissociation co-efficient (Kd) of chemokine dimers by 





Leary and collaborators have applied mass spectrometry to the study of chemokine 
oligomerisation and GAG binding.  For example, they observed that certain 
chemokines were capable of forming heterodimers in the presence of GAG.14  In 
another study, the pentasaccharide fondaparinux was found to preferentially bind 
dimers of the chemokine CCL2.15  This GAG-bound complex was more resistant 
towards collision-induced dissociation than the dimer alone. 
Despite the fact that the monomeric proteins of different chemokine sub-families 
have a common three-dimensional structure, the CC and CXC chemokine dimers 
have distinct arrangements of the subunits.  In CC chemokines the dimer interface 
generally occurs between residues near the N-terminus, whereas CXC chemokines 
tend to dimerise at the first -strand.  This difference in quaternary structure had 
previously been used to justify the selectivity of the receptors for a particular 
chemokine sub-family, however, it is now believed that it is the monomeric protein 
that interacts with the GPCR.16  Clark-Lewis and co-workers synthesised a mutated 
form of the chemokine CXCL8 that was unable to form a dimer and demonstrated 
that the monomeric analogue possessed the same ability to chemoattract cells in vitro 
as the wild-type protein.16  This is supported by a similar study in which the 
prevention of CCL2 dimer formation did not lead to loss in activity in vitro.10  In 
contrast, it has been demonstrated that the dimerisation of CCL2 and other 
chemokines is necessary to induce cell migration in vivo.10  This implies that 
although it is the monomer that binds and activates the receptor, oligomerisation is 
necessary for some other facet of the chemotaxis process in vivo.  One possibility is 
that the increased aggregation of chemokines decreases their susceptibility to 
proteolysis. 
Several studies have investigated the multimeric state of -defensins.  Most -
defensins have been observed to exist predominantly as monomers in solution.4, 17, 18  
By X-ray crystallography, HBD2 was found to exist mainly as a dimer in the solid-
state, with an octameric species also present.19  The dimer is formed via interactions 
between the first -strands of each monomer, creating a six-stranded -sheet.  In 
solution HBD2 is a monomer at sub-millimolar levels4, 18 but a dimer at elevated 





methods, although the dimer interface could not be identified by homonuclear 
NMR.4 
In contrast, very few studies have considered the interaction of -defensins with 
glycosaminoglycans.  McCullough et al. examined the conformational changes of a 
series of defensin-related peptides upon binding a heparin-derived disaccharide.20  
Schmidtchen and co-workers reported that an -defensin binds dermatan sulfate.21  
Both of these studies found that GAG binding diminished the antimicrobial activity 
of canonically-folded defensins.  Neither study reported GAG-induced 
oligomerisation of defensins nor considered GAG binding in the context of 
chemotaxis. 
In a very recent study, conducted in parallel with the research contained in this 
thesis, Seo et al. used a gel mobility shift assay (GMSA) and NMR spectroscopy to 
probe the binding of GAGs to HBD2.22   Using a range of heparin oligosaccharides, 
the GMSA indicated that tetrasaccharide was the minimum size of oligosaccharide 
required for binding to HBD2.  Two GAGs, a pentasaccharide (fondaparinux) and a 
hexasaccharide (dermatan sulfate), were studied by NMR.  The findings are 
discussed in more detail later in this chapter but, in brief, both GAGs bound HBD2. 
Given the apparent similarity of -defensins and chemokines, this chapter 
investigates the interaction of -defensins and glycosaminoglycans by mass 
spectrometry and ion mobility-mass spectrometry.  The potential implications for 
chemotactic activity are discussed. 
5.2 Experimental 
5.2.1 Peptide synthesis and glycosaminoglycans 
The peptides HBD2 and HBD3 were chosen as examples of natively-folded, 
chemotactic -defensins.  HBD2 was produced by recombinant expression in E. coli  
and purified by Emily Seo as described previously.23  HBD3, produced by solid-
phase synthesis, was purchased from the Peptide Institute (Osaka, Japan). 
Three glycosaminoglycans were used in this study: heparin dp4, fondaparinux and 





Figure 5.2 Structures of glycosaminoglycans used in this study 
 
Structures of: (a) heparin dp4; (b) fondaparinux; (c) dermatan sulfate dp6. 
Heparin and fondaparinux are oligosaccharides used to mimic heparin sulfate.  
Heparin sulfate occurs in all animal tissues and binds a variety of proteins in its 























































































because of its possible interaction with human -defensins 2 and 3, which are both 
expressed in epithelial cells.26 
Fondaparinux sodium was a gift from GlaxoSmithKline.  Heparin dp4 and dermatan 
sulfate dp6 were prepared by Conny Johansson and Haris Panagos using an 
enzymatic digestion protocol as described.27 
5.2.2 Mass spectrometry 
Stock solutions of the glycosaminoglycans were prepared at 1 mg/ml in water and 
dialysed overnight versus water using a 1,000 molecular weight cut-off Micro 
DispoDialyzer (Harvard Apparatus, MA, USA).   Samples were prepared in 20 mM 
ammonium acetate (pH 6.8) at 1:1 molar ratios of GAG to HBD2 or HBD3.  The 
final peptide concentration was 135 M.  Mass spectra were recorded on a Q-ToF II 
mass spectrometer (Waters, Manchester, UK), with ions produced by positive nano-
electrospray ionization.  Identical tuning conditions were employed for each sample.  
Photographs of the nano-electrospray tips were obtained using an LCD digital 
microscope (Aigo, Beijing, China) at 100x magnification. 
5.2.3 Ion mobility-mass spectrometry 
Samples of HBD2, HBD2 plus fondaparinux and HBD3 were prepared as described 
above and analysed by IM-MS on the MoQToF as detailed previously.28  For these 
experiments, the temperature and pressure of helium in the drift cell was 
approximately 28 °C and 3.2 Torr respectively.  Measurements were made at eight 
different drift voltages from 60 to 15V. 
5.2.4 Estimation of collision cross-sections from PDB structures 
The following protein databank entries were downloaded: 1FD3 (X-ray crystal 
structure of HBD2 dimer)19, 1FQQ (NMR structure of HBD2 monomer)18 and 1KJ6 
(NMR structure of HBD3 monomer)4.  Using the Leap program in Amber 9, 
hydrogen atoms were added to the crystal structure of HBD2 and a limited energy 
minimisation was performed on the resulting structure.29  This procedure was not 
carried out for the NMR structures of HBD2 and HBD3, which contain explicit 
hydrogens.  The rotationally-averaged collision cross-section of each structure was 





the NMR data, collision cross-sections were calculated for each of the twenty lowest 
energy structures available.  For the crystal structure, the collision cross-section was 
calculated for the dimer and its monomer subunit. 
5.2.5 Chemotaxis 
The in vitro chemotactic activity of HBD2 towards cells expressing CCR6 was 
assessed in the presence and absence of GAG.  These experiments were performed 
by Kirsty Tyrrell as reported previously.31  For the assays with GAG, an equimolar 
amount of fondaparinux to HBD2 was used. 
5.3 Results and discussion 
5.3.1 Mass spectrometry 
Human -defensin 2 
The mass spectrum of HBD2 alone in 20 mM ammonium acetate buffer is shown 
overleaf (Figure 5.3a).  Charge states [M+3H]3+ to [M+5H]5+ are observed for the 
HBD2 monomer, in addition to a small peak corresponding to the [M+5H]5+ charge 
state of a HBD2 dimer (shown enlarged in Figure 5.4a).  From studying the peak 
intensities it can be concluded that the peptide exists predominantly as a monomer in 
solution at 135 M, in agreement with the observations of others by NMR 
spectroscopy.4, 17  The narrow charge state distribution of the monomer indicates that 
the peptide adopts a compact tertiary structure in solution.  This is clearly attributable 
to the three disulfide bonds in HBD2, which help to maintain a tight three-
dimensional fold.  
The HBD2 dimer was only seen clearly as a [M+5H]5+ ion; other charge states may 
be present also but the signal intensities are too weak to be detected.  The 
identification of a HBD2 dimer by mass spectrometry is interesting.  As discussed 
previously, the crystal structure of HBD2 is that of a dimer (or multiple thereof).19  
This is supported by a dynamic light scattering experiment that indicated that HBD2 
exists as a dimer in solution, but only at concentrations greater than 3 mM.  The 
concentration of peptide in those experiments was considerably higher than in the 
























Mass spectra of: (a) HBD2 only; (b) HBD2 plus fondaparinux; (c) HBD2 plus dermatan 
sulfate dp6; (d) HBD2 plus heparin dp4.  GAGs present at 1:1 ratio in spectra (b)-(d).  List of 
expected/observed masses given in Appendix 6. 






























Figure 5.4 Mass spectra of HBD2 in the absence and presence of glysoaminoglycan,  




















m/z 1620-1750 enlarged for mass spectra of: (a) HBD2 only; (b) HBD2 plus fondaparinux; (c) 
HBD2 plus dermatan sulfate dp6; (d) HBD2 plus heparin dp4.  Unlabelled peaks correspond 
to sodium adducts of the preceding labeled species. 
The electrospray ionisation of proteins is believed to proceed mainly according to the 
‘charged residue’ model,32 where the evaporation and fission of solvent droplets 
produces a desolvated analyte ion.33  In droplets containing more than one molecule 
of interest, the analyte concentration is enriched.34  Thus the electrospray process 


















may provide the elevated levels of peptide required to observe the HBD2 dimer.  It is 
worth noting that dimeric species are not observed for several similar peptides 
studied by nESI-MS (see previous chapters). 
Human -defensin 2 plus glycosaminoglycan 
Upon the addition of an equimolar amount of fondaparinux to HBD2, a complex 
composed of a peptide dimer plus one GAG molecule is observed (Figure 5.3b).  On 
the Q-ToF II instrument, charge states [M+5H]5+ to [M+6H]6+ are observed for this 
species.  The stoichiometry of the binding is very specific: only a dimer-GAG 
complex is observed, with no monomer-GAG complex detected.  A small amount of 
unbound HBD2 dimer is evident in the spectrum, in addition to a large amount of 
free monomer.  The recent work of Seo et al. supports the observation of a 2:1 
HBD2:fondaparinux complex: the diffusion coefficient of the peptide-GAG complex, 
as determined by NMR spectroscopy, suggests that HBD2 exists mostly as a dimer in 
this form.22 
The 2:1 stoichiometry of the peptide:GAG complex observed for HBD2 is common 
among many chemokines.1  Thus this result represents further evidence of the ability 
of a -defensin to behave like a chemokine.  Leary and co-workers discovered that 
fondaparinux preferentially binds dimers of the chemokine CCL2 rather than 
monomers,15 a finding that is consistent with the specific binding observed in this 
experiment. 
The absence of any 1:1 HBD2:fondaparinux complex implies that in solution GAG 
binding occurs after formation of the defensin dimer.  The intensity of the unbound 
HBD2 dimer in the spectrum is the same (1.3% of base peak intensity) before and 
after the addition of GAG.  However there is significantly more dimer present in the 
spectrum, in the form of the GAG-bound complex, upon the addition of 
fondaparinux.  Crystallography revealed the presence of a proline residue along the 
dimer interface of HBD2 that sterically prohibits extensive hydrogen bonding 
between the -strands of the two monomer units.19  Consequently, the HBD2 dimer 
is weakly held together and (presumably) can be easily disrupted.  It would appear 
that electrostatic interactions between the very negatively-charged fondaparinux 





GAG may help to drive the formation of HBD2 dimer by bringing two monomers in 
close proximity (although, as stated above, GAG binding must occur after dimer 
formation).  Presumably the original amount of unbound HBD2 dimer is then 
restored by a shift in the equilibrium between monomeric and dimeric peptide 
according to Le Châtelier’s principle. 
A 2:1 peptide:GAG complex is also detected when an equimolar amount of a 
different GAG, dermatan sulfate dp6, is added to a solution of HBD2.  However this 
species is of much weaker intensity than the HBD2-fondaparinux complex (Figure 
5.3c and enlarged, Figure 5.4c).  Again, no 1:1 peptide-GAG binding is observed.  
The difference in HBD2 binding affinity between fondapariunx and dermatan sulfate 
hexasaccharide is likely due to the relative sulfation of the polysaccharides.  
Fondaparinux has a higher net charge (10-) than the hexasaccharide (6-) and so 
would be expected to interact more strongly with the positively charged -defensin.  
Although fondaparinux is a synthetic polysaccharide, the preference of HBD2 to 
bind one GAG more strongly than another is of interest because of the potential role 
of GAGs in cell signalling. 
In contrast, Seo et al. did not observe a 2:1 complex by NMR upon the addition of 
dermatan sulfate dp6 to HBD2: the diffusion coefficient is consistent with a 
monomeric peptide.22  A possible explanation is that the diffusion coefficient is a 
weighted average of more than one species and the dimeric complex is of very low 
abundance relative to the monomeric peptide, as indicated by the mass spectrum. 
Upon addition of a different GAG, heparin dp4, a 2:1 peptide:GAG complex is 
observed also (Figure 5.3d and Figure 5.4d).  In addition, a 1:1 complex is evident at 
the [M+4H]4+ charge state.  Others have shown that the size and flexibility of the 
oligosaccharide are important to the nature of the chemokine-GAG interaction.35  For 
example, a heparin octasaccharide was found to bind CCL2 dimers exclusively, 
whereas fondaparinux gave a mixture of dimer-GAG and monomer-GAG 
complexes.36  The authors attribute this lack of selectivity to the pentasaccharide 
being of insufficient length to bridge the GAG binding sites of the CCL2 dimer.35  In 
the experiments described here, both the pentasaccharide fondaparinux and the 





HBD2 (41 residues) is somewhat smaller than CCL2 (76 amino acids), it appears that 
the pentasaccharide is long enough to span both monomer units in the case of HBD2 
but not CCL2.  In contrast, heparin dp4 binds HBD2 monomers and dimers.  This 
lack of selectivity suggests that the tetrasaccharide is too short to bridge the GAG 
binding site of the HBD2 dimer.  
In the only other mass spectrometry-based investigation of -defensins and GAG 
interactions to date, McCullough et al. did not observe GAG-induced dimerisation 
for several murine -defensins and related peptides.20  In addition to differences in 
the peptides studied, the lack of oligomerisation is probably due to the small chain 
length of the heparin-derived disaccharide used. 
In an attempt to quantify the dissociation constant of the GAG-bound dimer, other 
ratios of HBD2 to fondaparinux were studied: solutions at 2:1, 10:1 and 20:1 
HBD2:GAG were prepared and analysed by mass spectrometry (Appendix 7).  
Unfortunately, it was not possible to determine the Kd of the HBD2-fondaparinux 
complex due to fluctuations in the abundance of the GAG-bound dimer with 
increasing saccharide concentration.  Jansma et al. recently reported a similar effect, 
in which in they observed fluctuations in the NMR diffusion co-efficient of the 
chemokine CCL2 in an assay with a heparin octasaccharide.37  With increasing 
amounts of GAG, they observed an initial increase in the oligomerisation state of 
CCL2 from monomer to dimer and then to tetramer.  Upon the addition of further 
GAG, the tetramer reversed to dimer.  Although no higher order oligomers (beyond 
dimer) were observed in this experiment, it would appear that the GAG-induced 
oligomerisation of HBD2 is a complicated process.  It is possible that higher order 
oligomers of HBD2 do occur on this pathway in solution but are not amenable to 
detection by mass spectrometry (see study of HBD3, below). 
Human -defensin 3 
The effect of different glycosaminoglycans has been discussed above: now a 
different peptide, human -defensin 3, is considered.  Shown below is the mass 
spectrum of HBD3 in 20 mM ammonium acetate in the absence of GAG (Figure 5.5a 





charge state distributions: the most intense belonging to the monomer and the other 
relating to the dimer.  
HBD3 was found to exist as a dimer in solution-phase studies at 360 M.4  In this 
experiment, at 135 M, the HBD3 monomer is the major species in the mass 
spectrum.  At this somewhat lower concentration, the equilibrium in solution 
between the monomer and dimer would be expected to shift slightly towards the 
dissociated peptide.  In addition, although some intact dimer is still observed, it is 
possible that the non-covalent interactions between the HBD3 monomer units are not 
strong enough to preserve all of the dimer ions in the gas-phase.  This is supported by 
comparison of the charge state distributions of the monomer and dimer.  The highest 
charge state observed for the monomer is at z = 6+, whereas it is z = 7+ for the dimer. 


















Mass spectra of: (a) HBD3 only; (b) HBD3 plus heparin dp4; (c) HBD2 plus dermatan sulfate 
dp6.  GAGs present at 1:1 ratio in spectra (b) and (c).  List of expected/observed masses 
given in Appendix 8. 
























Despite being double the mass of the monomer, the maximum number of protons 
carried by the dimer is just one greater.  In part, this is due to the conformation of the 
peptides in solution: the dimer interface may obscure some basic residues that would 
otherwise readily accept a proton.  Although the structure of the HBD3 dimer has yet 
to be solved, for comparison, only 18% of the HBD2 monomer unit is obscured upon 
forming a dimer.19  Therefore this effect alone does not fully account for the 
relatively low charge carried by the HBD3 dimer.  It is likely that those dimers that 
acquire a charge greater than z = 7+ in solution are overcome by Coulomb repulsion 
in the gas-phase and dissociate to monomers before they reach the detector. 
Figure 5.6 Mass spectra of HBD3 in absence and presence of glycosaminoglycan, 















Mass spectra of: (a) HBD3 only; (b) HBD3 plus heparin dp4; (c) HBD2 plus dermatan sulfate 
dp6.  GAGs present at 1:1 ratio in spectra (b) and (c). 














Human -defensin 3 plus glycosaminoglycan 
Upon addition of an equimolar amount of fondaparinux to HBD3, a precipitate was 
observed to form in the nano-electrospray tip (Figure 5.7).  No particulates were 
observed in the individual solutions of HBD3 or fondaparinux prior to mixing.  This 
effect was reproducible and was observed upon the addition of heparin dp4 also 
(Appendix 9).  The presence of insoluble matter in the spray solution resulted in 
clogging of the nano-electrospray tip and severely impeded ionisation of the sample. 
Figure 5.7 Precipitation of HBD3 upon addition of fondaparinux 
 
Photographs of nESI tips containing: (a) HBD3 only; (b) fondaparinux only; (c) HBD3 plus 





It was possible to obtain a steady spray by centrifuging the HBD3-GAG mixture and 
using only the supernatant for analysis.  In the case of HBD3 plus fondaparinux, no 
protein or protein-GAG complex peaks were detected in the resultant mass spectrum 
(data not shown).  For HBD3 plus heparin dp4, peaks corresponding to 1:1 and 2:1 
peptide:GAG complexes were observed (Figure 5.5b and enlarged, 5.6b).  No 
precipitation was observed upon the addition of dermatan sulfate dp6: this also 
formed both 1:1 and 2:1 peptide:GAG complexes.  The observation of both 1:1 and 
2:1 peptide GAG complexes indicates that heparin dp4 and dermatan sulfate dp6 do 
not bind either monomer or dimer selectively.  This perhaps indicates that the 
distance between the two GAG binding sites is greater in the HBD3 dimer compared 
to the HBD2 dimer. 
The observation of precipitate in the HBD3-fondaparinux solution could be 
attributable to higher order oligomers which, as insoluble aggregates, are not 
amenable to nESI mass spectrometry.  This hypothesis is supported by the reports of 
others studying chemokine-GAG interactions: peptide precipitation upon the addition 
of GAGs can result in the attenuation of NMR signal and is believed to occur due to 
extensive oligomerisation of the peptide.22, 37  It remains to be proven whether or not 
the monomer-GAG and dimer-GAG complexes observed by MS represent precursors 
to larger, insoluble oligomers in the aggregation process.  Notably, GAGs also 
promote the formation of amyloid fibrils, which are insoluble protein aggregates.38 
If this hypothesis is correct, it suggests that HBD3 binds fondaparinux most strongly 
(precipitates, no peptide observed in supernatant), followed by heparin dp4 
(precipitates, some peptide in supernatant), then dermatan sulfate dp6 (no 
precipitation).  Thus, the binding affinity increases with increasing sulfation of the 
GAG, as observed previously with HBD2.  Work is currently underway to confirm 
the binding of GAGs to HBD3 by means of a gel mobility shift assay. 
5.3.2 Ion mobility-mass spectrometry 
Human -defensin 2 
The rotationally-averaged collision cross-sections measured for the HBD2 monomer, 





in previous chapters, the collision cross-section of each species increases with charge 
state as a result of increased Coulomb repulsion.39, 40  It can be seen from the 
[M+4H]4+ and [M+5H]5+ charge states that the collision cross-sections of the 
unbound and GAG-bound HBD2 dimers are indistinguishable within experimental 
error.  Thus it can be concluded that any change in peptide conformation that occurs 
upon binding the polysaccharide does not result in a drastic change in the overall size 
of the complex, implying that the HBD2 dimer contracts to accommodate the extra 
size of the GAG.  When compared to the cross-sections of the monomer at the same 
charge state, both the free dimer and the GAG-bound complex are much more 
compact than might be expected.  For example, the HBD2 dimer is only 20% larger 
than the monomer at the [M+4H]4+ charge state.  It would seem that the higher 
density of charge on the monomeric peptide results in greater gas-phase unfolding 
due to Coulomb repulsion. 
Table 5.1 Mean collision cross-sections (Å2) of HBD2 monomer, dimer and 
fondaparinux-bound complex 
Charge state HBD2 monomer HBD2 dimer HBD2 dimer + fondaparinux 
[M+3H]3+ 598 ± 3 n.o. n.o. 
[M+4H]4+ 622 ± 4 760 ± 16 765 ± 10 
[M+5H]5+ 675 ± 3 957 ± 6 919 ± 25 
[M+6H]6+ 711 ± 11 n.o. 1072 ± 4 
[M+7H]7+ n.o. n.o. 1142 ± 3 
Errors are quoted as the standard error of the mean.  Species marked n.o. were not 
observed in sufficient intensity to accurately determine collision cross-sections by IM-MS. 
The collision cross-sections of HBD2 calculated from the PDB entries are shown in 
Table 5.2 and compared to experimental data in Figure 5.8.  For the monomer, the 
cross-section of the lowest charge state observed by IM-MS is approximately 100 Å2 
smaller than that calculated for the NMR structure.  As discussed previously, this 
more compact conformation results from a ‘hydrophobic collapse’ of the peptide 
structure upon transfer from solution to the gas-phase.41 Thereafter, the peptide 





charge state of HBD2 in the gas-phase has a collision cross-section similar to that of 
the monomer in solution. 
Table 5.2 Collision cross-sections (Å2) of HBD2 calculated from protein databank 
entries 
 HDB2 monomer HBD2 dimer 
NMR spectroscopy 706 n/a 
X-ray crystallography 717 1121 
The above values were calculated using the trajectory method.  The NMR value of the 
monomer is given as the mean collision cross-section of the twenty lowest energy structures 
in PDB 1FQQ. The crystallography values for the dimer and its monomer subunit were 
obtained from PDB 1FD3. NMR data for the HBD2 dimer is not available. 
Figure 5.8 Collision cross-sections of HBD2: gas-phase data compared to calculated 













The dotted line indicates the mean collision cross-section calculated for the twenty lowest 
energy NMR structures of the HBD2 monomer.  The dashed line indicates the collision 
cross-section calculated for the crystal structure of the HBD2 dimer.  Experimental data are 
shown as squares or diamonds. 
 






























The gas-phase collapse of HBD2 is even more pronounced for the dimer, with the 
[M+4H]4+ charge state being approximately 450 Å2 more compact than the crystal 
form.  It is striking that the lowest observed charge state of the HBD2 dimer is 
almost as compact as the monomer: there is only a 22% increase in size between 
monomer and dimer with z = 4.  There are few documented examples of such a 
dramatic hydrophobic compression, although Faull et al. observed only a 15% 
difference in the collision cross-sections of cytochrome c monomer and dimer ions.42 
Benesch et al. provide a relationship for estimating the collision cross-section of an 
ion, assuming a perfect sphere:34  















where  is the collision cross-section; m is mass;  is density (assumed to be 0.84 Da 
Å-3 for proteins) and rg is the radius of the buffer gas (1.4 Å for helium).  Using this 
relationship, the expected cross-section of the HBD2 monomer is 460 Å2 and 700 Å2 
for the HBD2 dimer.  Thus the measured cross-section of the HBD2 dimer is 
reasonable and consistent with a spherical shape of constant protein density.  This 
gas-phase conformation must arise from the significant compression of two 
monomeric structures that are somewhat more extended than a theoretical sphere. 
It was not possible to measure the cross-section of the HBD2-dermatan sulfate 
complex as a result of the very weak intensity of this species.  With HBD2 in the 
presence of heparin dp4, only the [M+4H]4+ charge state of the monomer-GAG 
complex and the [M+6H]6+ charge state of the dimer-GAG complex were observed 
in sufficient abundance to allow measurement by IM-MS (Appendix 11).  The cross-
sections of these species are consistent with the measurements in Table 5.1. 
Human -defensin 3 
As expected, the collision cross-sections of HBD3 (Table 5.3) are larger than those 
of HBD2 (Table 5.1), which is four amino acids shorter.  The increase in size from 
[M+3H]3+ to [M+6H]6+ is similar (approximately 110 Å2) for both HBD2 and HBD3 





883 Å2), reveals once more that the peptide adopts a more compact geometry in the 
gas-phase (Figure 5.9). 
Precipitation of the HBD3-fondaparinux complex prohibited analysis by IM-MS, 
whist it was not possible to measure the cross-sections of the HBD3-dermatan sulfate 
complexes on account of their low abundance.  Only the [M+5H]5+ charge state of 
the HBD3 monomer-heparin dp4 complex was observed in sufficient intensity for 
ion mobility measurements (Table 5.3).  The cross-section of the GAG-bound 
monomer is slightly larger than the unbound monomer of the corresponding charge 
state (although within experimental uncertainty).  This suggests that the defensin 
monomer may not contract as much as the dimer upon GAG binding. 
Figure 5.9 Collision cross-sections of HBD3: gas-phase data compared to calculated 













The above values were calculated using the trajectory method.  The dotted line indicates the 
mean collision cross-section calculated for the twenty lowest energy NMR structures of the 
HBD3 monomer.  No NMR or X-ray crystallography data is available for the HBD3 dimer.  


























Table 5.3 Collision cross-sections (Å2) of HBD3 monomer and dimer 
Charge state HBD3 monomer HBD3 monomer + heparin dp4 HBD3 dimer 
[M+3H]3+ 679 ± 34 n.o. n.o. 
[M+4H]4+ 741 ± 37 n.o. n.o. 
[M+5H]5+ 745 ± 37 790 ± 40 n.o. 
[M+6H]6+ 790 ± 40 n.o. 1092 ± 55 
[M+7H]7+ n.o. n.o. 1434 ± 72 
Species marked n.o. were not observed in sufficient intensity to accurately determine 
collision cross-sections by IM-MS.  It was not possible to obtain replicate measurements for 
this data set: the experimental uncertainty is estimated at ± 5 %, based on the minimum 
precision of previous measurements. 
5.3.3 Chemotaxis 
It was observed that the presence or absence of fondaparinux did not significantly 
affect the chemotactic activity of HBD2 in vitro (Appendix 12).  Thus, it can be 
concluded that fondaparinux does not inhibit the binding of HBD2 to CCR6 and so 
HBD2 must bind the GAG at a different site to that at which it interacts with the 
chemokine receptor. 
For several proteins, GAG binding domains occur at ‘BBXB’ regions of the amino 
acid sequence (where ‘B’ denotes a basic residue and ‘X’ signifies a hydrophobic or 
other residue).9  For example, the chemokine CCL5 binds heparin at a cluster of 
basic amino acids (RKNR) situated in the loop between the second and third -
strands.43, 44  Inspection of the primary structure of HBD2 (Figure 5.10) reveals the 
presence of such a motif at residues 22-25 (RRYK).  These amino acids are also 
located in the loop between two -strands and may comprise the GAG binding 
domain of HBD2.  The identification of this postulated binding site is supported by 
NMR data, which show the chemical shifts of these residues (and the C-terminal 
lysines at residues 39 and 40) change significantly upon GAG binding.22  The 
‘BBXB’ motif is not present in HBD3 and so it is difficult to predict the GAG 
binding site of this peptide.  NMR spectroscopy and/or molecular modelling would 





Figure 5.10 Primary structure of HBD2 and HBD3 
 
 
Aligned amino acid sequences of HBD2 and HBD3.  The ‘BBXB’ motif present in HBD2 is 
underlined. 
5.4 Conclusions 
-defensins and chemokines have a number of structural features and functions in 
common.  In this chapter the ability of -defensins to form oligomers and to bind 
glycosaminoglycans has been demonstrated by mass spectrometry.  Dimers of human 
-defensins 2 and 3 were observed.  For HBD2, the number of dimeric species was 
increased by the addition of GAG: a 2:1 peptide-GAG complex, commonly observed 
for chemokines, was formed in the presence of fondaparinux and dermatan sulfate.  
The specific stoichiometry of these complexes observed by mass spectrometry shed 
light on the mechanism of complex formation in solution.  1:1 and 2:1 HBD3-GAG 
complexes were also detected.  In addition, the observation of precipitates may 
indicate that HBD3 forms higher order oligomers in the presence of some GAGs, 
although this could not be verified by mass spectrometry.  Given that crystals are 
known to promote inflammation,45 an extremely pro-inflammatory response could 
result if this precipitation was replicated in vivo. 
The oligomerisation of -defensins may be important in vivo for both chemotactic 
and antimicrobial activity.  Whilst it is likely that the monomeric peptide interacts 
with the chemokine receptor to induce chemotaxis,16 the oligomerisation of some 
chemokines is essential to their function in vivo.10  By forming higher order 
oligomers, -defensins may become more resistant to proteolytic enzymes. 
As discussed in previous chapters, the mechanism by which -defensins kill bacteria 
has yet to be fully resolved.  Some antimicrobial peptides function by creating a pore 
in the bacterial membrane: this requires the formation of higher order oligomers.46  
Alternatively, -defensins may act by disrupting the bacterial membrane in a ‘carpet’ 
mechanism,47 or by passing through the membrane and then acting intracellularly.48  
HBD2:      GIGDPVTCLKSGAICHPVFCPRRYKQIGTCGLPGTKCCKKP 





In either case, aggregation may enhance -defensin activity by increasing the local 
peptide concentration. 
The binding of GAGs to -defensins also has implications for chemotactic and 
antimicrobial activity.  It suggests that, like chemokines, -defensins may attach to 
GAGs on the surfaces of cells so that a concentration gradient can be established in 
vivo.  Immune cells would then be able to follow the increasing concentration of -
defensins to the appropriate site.  Although no effect was observed in the in vitro 
assays described in this work, others have shown that the addition of GAGs can 
inhibit chemotaxis in vivo.49  The GAG-binding site of chemokines can be blocked 
by binding the soluble GAG, thus preventing the chemokine from adhering to cell-
surface GAGs.  -defensins are implicated in several inflammatory diseases, 
including psoriasis and mastitis.50, 51  A possible therapeutic strategy could be to 
dampen the immune response by using a glycsoaminoglycan to antagonise the -
defensin. 
Previous studies have shown that GAG-binding can negate the antimicrobial activity 
of defensins.20, 21  Presumably this occurs as a result of the reduction of the 
defensin’s positive charge, which weakens the electrostatic attraction of the cationic 
peptide to the negatively-charged lipopolysaccharide of the bacterial cell wall.  Some 
bacteria have been reported to exploit this, enhancing their virulence by inducing the 
release of GAGs from host cells in order to counteract the antimicrobial peptides that 
form part of the host defense.52 
In short, the interaction of β-defensins and GAGs have biological consequences.  
Here mass spectrometry and ion mobility mass spectrometry have been used to 
provide insights into these interactions.  In addition, the substantial structural 
rearrangement of the HBD2 dimer observed by IM-MS represents further evidence 
of the possible collapse of peptide oligomers in the gas-phase. 
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6 Conclusions and outlook 
As bacteria continue to find new ways to evade antibiotics,1 so too must the human 
race find new ways to overcome bacteria.  Drugs based on β-defensins and other 
antimicrobial peptides could form part of our arsenal against infection in future.  
With a defensin derivative currently in preclinical development,2 that future may not 
be too far away.  A more thorough understanding of how the activities of β-defensins 
are related to their structures will lead to a more informed search for other clinically 
useful antimicrobial peptides.  This thesis attempts to explain the variation in 
biological activities observed for a range of β-defensin analogues using biophysical 
techniques. 
Previous work revealed that a cysteine near the C-terminus of the murine defensin 
Defb14 was crucial to its chemotactic activity.3  In this thesis, ion mobility-mass 
spectrometry was used to evaluate the unfolding behaviour of the peptide upon 
chemical modification of this residue.  In cases where modification was deleterious 
to biological activity, an expansion in gas-phase structure was observed under 
denaturing conditions.  This suggests that the altering cysteine residue affects the 
overall conformational preferences of the peptide. 
At the N-terminus of this peptide, mutation of the second amino acid (leucine) 
affected the chemotactic activity but IM-MS revealed no significant changes in 
tertiary structure.  Taken together with the results described above, it is proposed 
here that the C-terminal cysteine orientates the peptide so that the N-terminal leucine 
can interact directly with the receptor. 
Analysis of a series of N-terminal truncations revealed that antimicrobial activity was 
diminished upon the deletion of more than eleven amino acids from Defb14-1CysV.  
Using reversed-phase HPLC it was established that this variation in activity did not 
correlate with a change in hydrophobicity and so it is likely that a balance between 
both charge and hydrophobicity is required.  Furthermore, CD spectroscopy revealed 
that the removal of amino acids from the N-terminus resulted in a decrease in the 
propensity of the peptide to form an -helix.  To determine if this affects the 
peptide’s ability to kill bacteria, it would be interesting to investigate the mechanism 
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of antimicrobial action.  It would be possible to establish if the peptide forms pores 
in bacterial membrane by monitoring the electrical conductivity of membrane 
bilayers or measuring the permeabilisation of fluorescent dyes.4 
The ability of β-defensins to bind GAGs could be essential for their chemotactic 
activity in vivo.  In the final chapter of this thesis, the interaction of human β-
defensins 2 and 3 with glycosaminoglycans was studied.  Oligomerisation of both 
HBD2 and HBD3 in the presence of GAG was observed by MS.  Of particular 
interest was the identification of a 2:1 defensin-GAG complex that is characteristic 
of chemokines.  By establishing the stoichiometry of this complex, mass 
spectrometry was used to elucidate the mechanism of binding in solution.  In 
addition, by measuring the differences in intensities of defensin-GAG complexes in 
the mass spectrum, the relative affinity of various GAGs for defensins could be 
assessed. 
This research exploited the three main advantages of mass spectrometry for studying 
peptides: sensitivity, speed and specificity.  The sensitivity and speed of the 
technique made the synthesis and analysis of a large number of modified peptides 
feasible.  By studying a range of different mutations in various regions of the 
molecule, it was possible to assess the structure-activity relationships of Defb14.  
The specificity of MS allowed for the unambiguous characterisation of defensin-
GAG complexes on the basis of their mass.  By combining mass spectrometry with 
ion mobility mass spectrometry, information on the tertiary structure of the peptides 
was obtained. 
The disadvantage of ion mobility spectrometry is that it is intrinsically a low-
resolution technique, providing only a measure of the overall size of an ion.  In this 
thesis it is hypothesised that GAGs bind to HBD2 via a ‘BBXB’ motif: to verify this 
experimentally, other methods of analysis would be required.  Another concern is the 
extent to which a gas-phase conformation resembles the structure of a peptide in 
solution.  Since defensins interact with either a bacterial membrane or a cell receptor, 
it may be helpful to create a ‘membrane-like’ environment prior to ionisation by 
using surfactants.  This approach has been used to great success by the group of 
Robinson for the analysis of membrane-bound proteins by mass spectrometry.5 
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In conclusion, the work presented in this thesis elucidates structure-activity 
relationships for the peptide Defb14 and provides new insights into the structural and 
functional overlap between β-defensins and chemokines.  Yet, since every peptide 
and every organism behaves differently, the relationship between the structure and 
activity of antimicrobial peptides is complex and much more research is required 
before this is fully understood. 
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Appendix 1 Collision cross-sections (Å2) of Defb14, Defb14-1CysV and Defb14-0Cys 
under denaturing conditions 
 Defb14 Defb14-1CysV Defb14-0Cys 
[M+3H]3+ n.o. n.o. n.o. 
[M+4H]4+ 709 n.o. n.o. 
[M+5H]5+ 751 916 n.o. 
[M+6H]6+ 881 962 979 
[M+7H]7+ 1008 1018 1070 
[M+8H]8+ n.o. 1105 1170 
[M+9H]9+ n.o. n.o. n.o. 
Species marked n.o. were not observed from IM-MS. 
The above data is taken from: B. J. McCullough, J. Kalapothakis, H. Eastwood, P. Kemper, 
D. MacMillan, K. Taylor, J. Dorin and P. E. Barran, Anal. Chem., 2008, 80, 6336-6344. 
 
Appendix 2  Collision cross-sections (Å2) of Defb14, Defb14-1CysV and Defb14-0Cys 
under buffered conditions 
 Defb14 Defb14-1CysV Defb14-0Cys 
[M+3H]3+ - n.o. 659 ± 3 
[M+4H]4+ - 740 ± 12 798 ± 9 
[M+5H]5+ - 888 ± 23 1008 ± 7 
[M+6H]6+ - 986 ± 19 1076 ± 15 
[M+7H]7+ - 1053 ± 15 1086 ± 11  
[M+8H]8+ - 1125 ± 15 1116 ± 7 
[M+9H]9+ - 1216 ± 9 1185 ± 2 




Appendix 3 HPLC retention times of Defb14-1CysV and  
 N-terminal truncations, relative to melittin 
 Monomer Dimer 
Defb14-1CysV 0.630 0.705 
(1-2) 0.639 0.728 
(1-5) 0.633 0.719 
(1-8) 0.599 0.688 
(1-11) 0.377 0.459 
(1-14) 0.407 0.493 
(1-17) 0.500 0.627 
Increasing relative retention time indicates increasing hydrophobicity. 
 
Appendix 4 Wimley White scores hydrophobicity scores for  
 Defb14-1CysV and N-terminal truncations 
 Monomer Dimer 
Defb14-1CysV -13.56 -27.12 
(1-2) -15.25 -30.50 
(1-5) -13.67 -27.34 
(1-8) -12.43 -24.86 
(1-11) -14.52 -29.04 
(1-14) -13.21 -26.42 
(1-17) -12.38 -24.76 
A less negative score indicates increasing hydrophobicity. 




Appendix 5 CDSSTR analysis of Deb14-1CysV, N-terminal truncation and N-terminal 
substitution peptides 
All of the peptides analysed contained the following secondary structural elements in 
10 mM ammonium acetate buffer. 
 Basis set 4 Basis set 7 
Helix (%) 7 ± 1 4 ± 1 
Strand (%) 35 ± 2 30 ± 2 
Turn (%) 23 ± 1 16 ± 1 
Unordered (%) 33 ± 1 49 ± 2 
Analysis was performed using two different basis sets: basis set 7 includes denatured 
proteins and so gives a higher estimate of unordered structure.  The algorithm is only 
applicable to peptides/proteins in aqueous solution and so analysis was not performed for 




Appendix 6 Expected/observed masses of HBD2-GAG complexes 
Spectrum Species Expected mass (Da) Observed mass (Da)
(a) HBD2 monomer 4328.23 4328.21
 HBD2 dimer 8656.46 8656.30
(b) HBD2 monomer 4328.23 4328.16
 HBD2 dimer 8656.46 8656.20
 HBD2 dimer + fondaparinux 10164.65 10164.84
(c) HBD2 monomer 4328.23 4328.10
 HBD2 dimer 8656.46 8656.38
 HBD2 dimer + DS dp 6 10034.60 10034.70
(d) HBD2 monomer 4328.23 4329.09
 HBD2 monomer + heparin dp4 5483.17 5484.40
 HBD2 dimer 8656.46 8656.84
 HBD2 dimer + heparin dp4 9811.40 9813.75
The expected masses of fully de-salted, protonated GAGs are: fondaparinux 1508.19; 
dermatan sulfate dp6 1378.14; heparin dp4 1154.94. 
Observed masses were obtained by deconvolution of the corresponding charge states in the 
ESI mass spectra using the transform algorithm in MassLynx v4.1 (Waters).  
All masses are quoted as the average molecular weight. 
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Appendix 7 HBD2 plus fondaparinux at various ratios 














Ratios of HBD2 to fondaparinux: (a) 1:1; (b) 2:1; (c) 10:1; (d) 20:1 HBD2:GAG.  The number 
given on the y-axis corresponds to the relative intensity of the [M+6H]6+ complex peak, with 




Appendix 8  Expected/observed masses of HBD3-GAG complexes 
Spectrum Species Expected mass (Da) Observed mass (Da)
(a) HBD3 monomer 5155.19 5155.39
 HBD3 dimer 10310.38 10310.93
(b) HBD3 monomer 5155.19 5155.82
 HBD3 monomer + heparin dp4 6310.13 6311.33
 HBD3 dimer 10310.38 10312.06
 HBD3 dimer + heparin dp4 11465.32 11467.46
(c) HBD3 monomer 5155.19 5155.75
 HBD3 monomer + DS dp 6 6533.33 6534.31
 HBD3 dimer 10310.38 10312.21
 HBD3 dimer + DS dp 6 11688.52 11691.37
The expected masses of fully de-salted, protonated GAGs are: heparin dp4 1154.94; 
dermatan sulfate dp6 1378.14. 
Observed masses were obtained by deconvolution of the corresponding charge states in the 
ESI mass spectra using the transform algorithm in MassLynx v4.1 (Waters).  
All masses are quoted as the average molecular weight. 
 
 
Appendix 9 Precipitation of HBD3 in the presence of heparin dp4 
 





Appendix 10 Mass spectrum of HBD2 in presence and absence of fondaparinux, 















Mass spectra of: (a) HBD2 only; (b) HBD2 plus fondaparinux at 1:1 ratio.  Peaks marked with 
an asterisk (*) correspond to peptide fragments formed in source.  Note the elevated levels 
of the 2:1 HBD2:GAG complex.  A tetrameric (4:2) HBD2:GAG complex is also observed.  
The collision cross-section of the 4:2 complex was measured as 1654 ± 34 Ǻ2. 
 
Appendix 11 Collision cross-sections (Å2) of HBD2 complexes with heparin dp4 
Charge state HBD2 monomer + heparin dp4 HBD2 dimer + heparin dp4 
[M+4H]4+ 654 ± 33 n.o. 
[M+5H]5+ n.o. n.o. 
[M+6H]6+ n.o. 1022 ± 51 
Species marked n.o. were not observed in sufficient intensity to accurately determine 
collision cross-sections by IM-MS.  It was not possible to obtain replicate measurements for 
this data set: the experimental uncertainty is estimated at ± 5 %, based on the minimum 
precision of previous measurements. 
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The migratory index (ratio of the number of cells per high power field with peptide to number 
of cells media alone) is quoted as the mean ± the standard deviation.  In all cases the 
migratory index of the HBD2 in the presence and absence of fondaparinux is the same within 
experimental uncertainty. 



















 HBD2 + fondaparinux
124 
 
Appendix 13 Publications arising from this thesis 
 
‘Conformational preferences of linear β-defensins are revealed by ion mobility-mass 
spectrometry’ 
M. De Cecco, E. S. Seo, D. J. Clarke, B. J. McCullough, K. Taylor, D Macmillan, J. 
R. Dorin, D. J. Campopiano and P. E. Barran, J. Phys. Chem. B, 2010, 114, 2312. 
 
‘Isoleucine/leucine-2 is essential for chemoattractant activity of β-defensin Defb14 
through chemokine receptor 6’ 
C. Tyrrell, M. De Cecco, N. L. Reynolds, F. Kilanowski, D. Campopiano, P. Barran, 
D. Macmillan and J. R. Dorin, Mol. Immunol., 2010, 47, 1378. 
 
‘Peptide fragments of a β-defensin derivative with potent bactericidal activity’ 
N. L. Reynolds, M. De Cecco, K. Taylor, C. Stanton, F. Kilanowski, J. Kalapothakis, 
E. Seo, D. Uhrin, D. Campopiano, J. Govan, D. Macmillan, P. Barran and J. R. 
Dorin, Antimicrob. Agents Chemother., 2010, 54, 1922. 
 
‘Interaction of human β-defensin 2 (HBD2) with glycosaminoglycans’  
E. S. Seo, B. S. Blaum, T. Vargues, M. De Cecco, J. A. Deakin, M. Lyon, P. E. 
Barran, D. J. Campopiano and D. Uhrin, Biochemistry, 2010, 49, 10486. 
